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The work presented in this thesis is aimed to design efficient reactive crystallization 
operations that could potentially be implemented in the manufacture of enantiomerically 
pure compounds and β-lactam antibiotics. Multiple aspects of solution thermodynamics, 
reaction engineering and crystallization from complex solutions are involved and will be 
discussed in detail through the following chapters.  
The first piece of this work utilizes reactive crystallization for the manufacture of 
enantiomerically pure amino acids.  Chemo-enzymatic stereoiversion reactions are used 
to enrich saturated or supersaturated solutions to favor the selection of a desired 
enantiomer. L-Methionine and L-Phenylalanine were resolve successfully from racemic 
mixtures by cyclic stereoinversion. r D-amino acids were oxidized by D-amino acid 
oxidase (D-AAO) and the resulting ketoacid was subsequently reduced by ammonia 
borane producing a racemic-mixture   After the necessary enantiomeric enrichment was 
reached,  system conditions were changed to induce supersaturation and promote crystal 
formation.  In each case crystals with chemical and enantiomeric purities greater than 
99% wt. were recovered. experimental information about reaction and crystallization 
kinetics was used to developed models. Such models were used to design model-based 
optimizations in which the productivity of the operation was enhanced by selecting an 
optimal temperature profile. 
The second example is a reactive crystallization towards the manufacture of β-lactam 
antibiotics. One of the major drawbacks of the utilization of enzymes towards the 
manufacture of β-lactam antibiotics is the fact that the same enzyme that catalyzes the 
xx 
 
synthesis of the antibiotic also catalyzes its hydrolysis and thus, its degradation. The 
reaction scheme is a kinetically controlled synthesis in which the desired product is an 
intermediate within the network.  Hence, the focus of this work is to design an efficient 
reactive crystallization in which the product is crystallized before it is consumed by 
hydrolysis. In order to accomplish this goal we have study solution equilibria, reaction 
kinetics, and crystallization kinetics.  Even though crystallization kinetics of ampicillin 
has been previously reported; the reported models are not applicable to a reactive 
crystallization scheme for a variety of reasons. In this work, we have developed a robust 
model that can be applied to multiple crystallization protocols that are consistent with the 
conditions at which the enzymatic reaction can be performed. 
 Finally, a reactive-crystallization scheme in which ampicillin was successfully 
recovered from solution was developed.  In this work, crystal seeds were used to promote 
crystallization of the desired product from the complex media. The results indicated that 
is possible to perform the reaction and crystallization in parallel, and still recover crystals 
with high purity. This work is the first example in which ampicillin was produced and 
recovered with high purity in a single stage. Previous work on reaction crystallization of 
antibiotics reported ampicillin crystallization; however, this was accompanied by 
precipitation of by-products which greatly reduces the applicability of the operation as 
product purification is required after the reaction. 







1.1 Manufacture of enantiomerically pure compounds 
Enantiomers are non-superimposable mirror image compounds.  As a result, these will 
exhibit the same chemical properties differing only on their spatial orientation. This attribute is 
very important since the majority of molecules in biological systems exist as a single orientation. 
For example, amino acids of a protein will exhibit an L-orientation. This preferred orientation is 
consistent through almost every molecule in life. Such topic has been an unsolved question, 
where researchers have been trying to explain the selective evolution towards a specific 
orientation (Blackmond, 2010). For this reason, enantiomeric orientation is a critical factor in the 
development of pharmaceuticals as different orientations will interact differently with the body. 
Probably, the most remarkable example of this dual interaction is thalidomide. This drug was 
synthesized in 1964 by CIBA pharmaceutical company, and prescribed as tranquilizer and 
antimetic for morning sickness (Franks et al., 2004). However, it ended up causing multiple 
congenital defects to approximately 10,000 children worldwide. This undesired effect is believed 
to be cause by one of the enantiomeric orientations. Further, examples includes a significant 
number of high volume prescribed medications such as Lipitor (Pfizer), Plavix (Bristol Myers-
Squibb), and Advair (Glaxo Smith Kline), and common over the counter medications such as 
analgesics, anti-inflammatories, and acid reflux inhibitors. As a result of investigations on this 
area, the Food and Drug Administration (FDA) and other international regulatory agencies 
require both chemical and enantiomeric purity on APIs unless the counter enantiomer is proven 





There are two main routes in which enantiomerically pure compounds can be obtained: 
(1) selective synthesis/consumption and (2) separation of racemic mixtures. In the first route 
(synthesis/consumption), enantioselective reactions can be achieved through the utilization of an 
enantioselective catalysts. These catalysts can be either organic/inorganic or biochemical. 
Catalysts enable reactions that can enrich the enantiomeric excess through asymmetric synthesis 
(i.e. just producing a single enantiomer) or by consuming one of the enantiomers of a racemic 
mixture (Kroutil et al., 1998; Wolf, 2007).  
Alternatively, enantiomerically pure compounds can be obtained through separation 
and/or purification of racemic mixtures. This option is predominant due a lack of asymmetric 
catalysis towards the production of a significant number of compounds. Usually, when an 
organic synthesis is performed without the presence of a chiral catalyst there is an equal 
probability of synthetizing either enantiomer. As a result, the product of such reaction will be a 
racemic mixture that contains equal concentrations of both enantiomers.  At this stage, the 
product can be processed through a separation train to obtain a solution or solid whose only 
solute is the desired enantiomer. In most cases, this separation involves chiral chromatography or 
chiral crystallization. Chiral chromatography involves the utilization of a stationary phase that 
contains chiral ligands (E. Francotte, 2009; E. R. Francotte, 2001). Recently, this principle has 
been extended to simulated moving beds (SMBs), where the productivity of the separation is 
improved by changing the inlet/outlet of the solution resulting on an optimal usage of the column 
(E. Francotte et al., 2002). 
Enantioselective crystallization (or chiral crystallization) requires understanding the 
kinetics and equilibrium of the system of interest. This type of crystallization can be classified 





and (3) crystallization of enantioenriched solutions. The first one exploits crystallization kinetics 
to achieve the separation as crystallization of one enantiomer is temporarily preferred over its 
counterpart. This preference is based on seeding a solution with the desired orientation and 
recovering the crystals before the solution concentration returns to equilibrium. Crystallization of 
diastereomeric salts employs chiral reagents to form salts whose thermodynamic properties 
(solubility) differ from each other, thus breaking the symmetry of the system. These salts are 
eventually resolved with strong acids or bases to recover the pure enantiomers. Lastly, 
crystallization from enantioenriched solutions simply refers to crystallization from a solution in 
which the formation of an enantiomerically pure crystal is thermodynamically favored. Such an 
enantiomeric enrichment can be achieved by reactions or previous units of separation. 
In this work enzymatic reactions are being used to enrich the solution with respect to the 
desired orientation. Enzymes have been extensively used for the synthesis of enantiomerically 
pure compounds as they can offer great enantioselectivity. In this project, enzymes are being 
used to perform enantioselective oxidations. This reaction combined with a chemical reduction 
allows us to completely change the orientation of the undesired enantiomer into its counterpart. 
Additionally, reactions are performed at concentration levels that enable the recovery of the 
desired product while its sill being produced.  Such approach maximizes the productivity of the 
operation as will be explained later.  
 
 
1.2 Manufacture of β-lactam antibiotics 
β-lactam antibiotics are the class of antibiotics that contain a β-lactam ring within their 





amoxicillin, and cephalosporins, monobactams, and carbapenems. These type of antibiotics span 
approximately 65% of the world market for antibiotics, with sales greater than $15 billion 
(Elander, 2003; Giordano et al., 2006).  Commercial manufacturing of β-lactams antibiotics is 
usually achieved through conventional organic synthesis, where low temperatures, 
organochloride solvents,  and protection/deprotection groups are employed (Ospina et al., 1996). 
As a result, a significant amount of waste is generated through the process. For example, the E-
factor of cephalexin is approximately 35 kg of waste per kg of product (Wegman et al., 2001 
). Considering that this compound has an annual production of 3000 tons, the annual 
generation of waste exceeds 100,000 tons.  
An alternative route for manufacturing of β-lactam antibiotics is the enzymatic synthesis by 
penincillin G acylase (PGA). This enzyme can catalyze the acyl transfer from an activated side 
chain donor to the nucleophilic β-lactam forming the desired antibiotic. For example, the 
enzymatic synthesis of ampicillin can be achieved by reacting 6-aminopenicillanic (6-APA) acid 
and D-phenylglycine methyl ester (D-PGME) in the presence of PGA. Similarly, other β-lactam 
can be produced by PGA simply by changing the initial reactants.   
The overall reaction scheme is presented in Figure 1.1. As it can be seen in the figure, PGA 
does not only catalyze the synthesis of ampicillin but it also catalyze the hydrolysis of D-PGME 
to D-phenylglycine and the hydrolysis of ampicillin to D-phenylglycine and 6-APA. In fact, the 








Figure 1.1:  Enzymatic synthesis of ampicillin by PGA. 
As it can be observed in the figure, this system is a kinetically controlled reaction, where 
ampicillin is an intermediate within the network. Multiple reaction engineering strategies have 
been used to improve the yield of 6-APA towards ampicillin.  
 In this work we have developed a reaction-crystallization scheme that enables the 
recovery of ampicillin as it is produced by the synthesis reaction. Such a process has the 
potential of protecting ampicillin from secondary hydrolysis, which increases the yield of the 
operation. Additionally, separation and purification of the desired product is achieved while is 
being produced. Hence, the productivity of the operation is increased as the total manufacturing 








2.1 Crystallization Fundamentals 
2.1.1 Introduction 
Crystallization refers to the formation of a structured (crystalline) solid phase from a 
supersaturated solution. Such technique has been widely used for the separation and purification 
of specialty chemicals, food, and pharmaceuticals. Common techniques used to induce 
supersaturation include cooling, evaporation, anti-solvent addition, and precipitants addition. All 
of these rely on changing system thermodynamics such that the solubility of the solute is 
reduced.   
Although separation and purification can be a difficult task by itself, usually a 
crystallization process is design to meet not only purity and productivity targets, but crystals with 
the desired properties. These properties can include morphology, crystal size distribution (CSD), 
and minimization of impurity or solvent inclusion, etc. Such properties are considered as quality 
attributes as they affect the performance of the molecule. For example, it is very well know that 
the morphology and crystal size of an active pharmaceutical ingredient (API) affects its 
solubility and dissolution rate (Nagy et al., 2012). Additionally, CSD greatly affects post-
crystallization operations such as filtration and drying (Wibowo et al., 2001).  In order to control 
these properties, a thorough understanding of the crystallization process is necessary. This 
usually refers to obtaining information about crystallization kinetics, which relates the rate of 
nucleation and crystal growth to the level of supersaturation in the system (Mullin, 2001; 







2.1.2 Solution thermodynamics 
Solubility is defined as the maximum concentration of a solute at equilibrium with a solvent 
at given conditions. This maximum concentration is a function of multiple variables of the process 
such as temperature, pH, ionic strength, co-solvent fraction, and concentration of other solutes.  
Using a thermodynamic framework, equilibrium can be defined using the fugacity of solutes in 
each phase: 
,  ,i pure solid i solutionf f                                               (2.1) 
          ,  ,0i pure solid i i if x f                                               (2.2) 
where  γi  is the liquid phase activity coefficient, xi is the solubility (mole fraction), and 𝑓𝑖,0 is the 
fugacity at standards conditions. The selection of the standard state is arbitrary; thus, the fugacity 
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                                          (2.3) 
Utilizing a thermodynamic cycle the ratio of the fugacities can be related to the change of free 
energy of the system (Prausnitz et al., 1999). This can be used to relate the fugacities with 
physical parameters such as heat of melting, melting temperature, and the difference in sensible 
heat. 
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Finally, this equation can be used to relate the solubility with such physical parameters because 
the ratio of the fugacities is related to the solubility.     
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By assuming ideal solution and neglecting the effect of sensible heat, Equation 2.5 can be 
reduced to the commonly used Van’t Hoff equation, which relates solubility with the temperature 









                                                         (2.6) 
This expression is commonly used in the design of cooling crystallization protocols, as the 
temperature of the system is reduced to induce supersaturation. 
2.1.3 Phase diagrams 
 For practical purposes, the solubility of a particular solute in a solvent can be represented 
with a phase diagram. This type of diagram presents useful information related to the solubility of 
the compound of interest as a function of process variables such as temperature, pH, composition, 
and others. Figure 2.1 shows a generic phase diagram for a single component as a function of 
temperature. In such diagram we can identify the concentration at equilibrium at any particular 
temperature. The solubility curve divides the diagram in two possible phases; below the curve an 
undersaturated region exist where only a liquid phase is present, while above the curve the solution 






Figure 2.1: Pure component phase diagram as a function of temperature. 
Similarly, phase diagrams can be constructed using different variables such as pH, ionic strength, 
or composition. If multiple solutes can crystallize at the range of operation, a multicomponent 
phase diagram is necessary to describe the system. In future sections, such a diagram will be 
used to describe the solubility of chiral compounds as a function of temperature and counter-
enantiomer. 
2.1.4 Nucleation 
 The formation of new crystals from a supersaturated solution is referred as nucleation. This 
event can be classified as primary or secondary nucleation. Primary nucleation occurs when new 
crystals are created in the absence of previously formed crystals (seeds), while secondary 
nucleation refers to the creation of new crystals in the presence of seeds. Primary nucleation can 
be sub-classified in two categories: (1) homogeneous and (2) heterogeneous nucleation (Randolph 
et al., 1988). Homogeneous nucleation is refer to a spontaneous nucleation event that is not induced 
by the presence of foreign solid bodies (Mullin, 2001). On the other hand, heterogeneous primary 





multiple processes primary nucleation is assumed to be homogeneous, it is difficult to guarantee 
that the surface area of the crystallizer, blades, baffles, etc. are not influencing nucleation. 
The formation of new stable nuclei requires organization and clustering of solute molecules 
in solution (Larson et al., 1986b). However, prior the onset of nucleation an interchange of 
molecules between the cluster and solution will take place. This cluster would remain in solution 
until a nuclei critical size is achieved. Such critical size can be derived from solution 
thermodynamics by considering the change in free energy of the system (Larson et al., 1986a).  
First, the contributions of solute surface area and volume are considered as the total change in free 
energy of the system.  
A VG G G                                                                  (2.7)  
The contribution of the surface area to the change in free energy of the system it is assumed to be 
proportional to the change of total area times its surface tension.  
γA nG A                                                                    (2.8) 
Additionally, the contribution of the volume it is associated to the specific free energy change of 
the liquid-solid phase transformation. 
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Finally, by substituting the respective expressions in the total change in free energy of the 
system, an expression that relates this change with the dimensions of the nuclei can be obtained. 
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Nuclei critical size can be obtained by differentiating the change in free energy respect to length 











                                     (2.11)  
Figure 2.2 shows the change in free energy as a function of nuclei size. As it can be observed, 
whenever the positive contribution of the surface area is predominant, the nuclei will not reach 
its critical size and will remain in solution. This barrier is overcome when the supersaturation of 
the system it is high enough to make the volume contribution predominant. After this, the energy 
of the system will decrease by the creation of a new phase.  
 
Figure 2.2: Change in free energy of the system as a function of nuclei length. 
 
2.1.5 Growth 
 Crystal growth refers to the accumulation of solute molecules in an already existing crystal, 
resulting in an enlargement of the crystal size. As in nucleation, such a process is driven by the 
supersaturation in the system. There are multiple theories that explain this mechanism such as 
diffusion-reaction, surface energy, and layer adsorption theories. Diffusion-reaction explains the 
process by two steps. In the first step solute molecules diffuse from the bulk to the crystal surface, 
while in the second step solute molecules react with other molecules at the surface of the nuclei. 
Surface energy theory is based on the hypothesis that crystals will grow in the shape that minimize 





importance of surface imperfections to facilitate the deposition of solute molecules into the crystal 
lattice. 
2.1.6 Crystallization process 
In the previous sections solution thermodynamics, nucleation, and crystal growth were 
discussed; in this section, this information will be used to discuss crystallization processes. Figure 
2.3 shows a phase diagram as a function of temperature. It can be observed that the phase diagram 
it is divided in three different zones. The undersaturated region represents conditions that only a 
liquid phase can exist as the solubility has not been reached.  The metastable region represents 
conditions in which the solution it is supersaturated (i.e. concentration>solubility) but this 
supersaturation it is not sufficiently high to induce instantaneous nucleation. After the metastable 
limit, the liable region it is reached. In this region, supersaturation is sufficiently high to induce 
instantaneous nucleation. This process can be explained from classical nucleation theory. As 
discussed in Section 2.1.4, the change in free energy of the system is composed of area and volume 
effects. These effects are inherently associated with the supersaturation of the system. However, 
this process explains only primary nucleation. In fact, if a solution within the metastable is seeded 
with crystals of the solute, nucleation is possible at the surface of these seeds through secondary 
nucleation mechanisms. This technique is used for the separation of compounds with similar 






Figure 2.3: Solubility curve and metastable limit. 
To illustrate the process let’s consider Figure 2.4. The figure shows a cooling 
crystallization experiment of L-methionine (Encarnacion-Gomez et al., 2015). As it can be 
observed, at the beginning of the experiment the solubility curve it is above the solution 
concentration curve. Hence, at this point the solution is undersaturated and it is not possible to 
crystallize any product. As the temperature of the system is reduced, the solubility of the system 
changes accordingly to its temperature dependence. At some point, the solubility curve meets the 
concentration curve and the system enters the metastable region. As the solubility is still 
decreasing, supersaturation builds until the metastable limit is reached and nucleation occurs. 
After the first nuclei is created, supersaturation is depleted by a combination of nucleation and 
crystal growth. However, usually, as the concentration curves gets closer to the solubility curve 






Figure 2.4. Crystallization of L-methionine steps. 
2.1.6 Population balance and crystallization kinetics 
The formation of solid particles in a crystallizer can be described by population balance 
equations(Randolph et al., 1988). Equation 2.12 represents the evolution of the number of 



















                                                             (2.13) 
This equation is a partial differential equation; thus, both initial and boundary conditions are 
required for its solution.  Equations 2.14 and 2.15 are the typical conditions used to solve the 
population balance equations.  The initial condition represents the initial population at the 





condition can be derived from a material flux analysis and it represents the creation of a particle 
of a negligible size that is growing in some characteristic direction. 





                                                            (2.15) 
Numerical solution of PBE is achieved through multiple discretization methods as discussed 
elsewhere (Chang, 1995; Qamar et al., 2006).  Such methods deal with the high non-linearity of 
crystallization processes increasing the reliability and robustness of the models.                                                             
 Solution to population balance equations can be simplified by applying the method of 
moments. In this method, the moments of the distribution are related with cumulative properties 
of the system. For example, the zeroth moment represents the total number of particles with a 
dimension of zero (nuclei). The first moment represents particles of one-dimension; hence, it 
represents the summation the length of the particles in the system. 
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Differentiation of the moments leads to expressions that contain nucleation and growth kinetics: 
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This method has been extensively employed to model batch crystallization kinetics as the partial 
differential equation is transformed to an ordinary differential equation that can be easily solved 
with the appropriate initial conditions (Qiu et al., 1994).      
 





2.2.1 Enzymatic synthesis and resolution of chiral compounds 
 Biocatalysts are commonly used to manufacture enantiomerically pure compounds 
because of their high enantioselective.  Enzymes can perform different reactions such as 
reductions, oxidations, transaminations, and others. Usually, these reactions are performed at 
mild conditions in comparison with their chemical counterparts. Simon et al.(Simon et al., 1985) 
discussed the utilization of different microorganisms for the reduction of multiple aldehydes, 
carboxylic acids, ketones, and carboxylates. The selectivity of such reactions was found to be 
completely dependent on the substrate of interest. Bommarius et al. discussed the utilization of 
isolated enzymes towards the manufacture of enantiomerically pure amino acids (Bommarius et 
al., 1998, 2001). In their work, multiple processes such as hydantoinase/carbamoylases and 
reductive aminations are discussed. Hydantaoinase/carbamolyse is a two-step process; a 
hydantoin is first hydrolyzed to a carbamoylic acid and then converted to the amino acid. One of 
the key attributes of this process is that it can be easily adopted for the production of either L or 
D amino acids.  This attribute is critical as D-amino acids are not common in nature and have 
great utility in the synthesis of pharmaceutical compounds. Another route discussed is the 
reductive amination of keto acids to amino acids by amino acid dehydrogenases. Further 
examples include the production of chiral amines by amine dehydrogenases (Abrahamson, 
Bommarius, et al., 2012; Abrahamson, Vazquez-Figueroa, et al., 2012). Instead of accepting keto 
acids as an amino acid dehydrogenase, ketones are accepted as a substrate yielding chiral amines 
as a product. Although these reactions are of great utility in the manufacture of enantiomerically 
pure compounds, half of the raw materials is lost if the initial substrate is a racemic mixture. 






A significant number of chiral reactions deal with the transformation of a single 
enantiomer. In order to alleviate this issue, processes in which most of the racemic mixture is 
utilized have been developed. A remarkable example of such a process is seen in the 
manufacturing of aspartame. The yield of this operation can be double by the racemization of the 
undesired D-phenylalanine methyl ester (Boehm et al., 1984).  In this process, the undesired D-
phenylalanine methyl ester is continuously recycled and racemized. After multiple cycles, most 
of the undesired enantiomer has been converted and used in the final product. 
A different approach that can be used to obtain enantiomerically pure compounds is 
stereoinversion of undesired enantiomers (Alexandre et al., 2002; Gruber et al., 2006; Soda et al., 
2001). For example, amino oxidase has been used in combination of chemical reactions to obtain 
enantiopure products. This process can achieve streoinversion of chiral amino acids into a single 
enantiomer by a cyclic chemo-enzymatic stetroinversion.  The process starts by oxidizing the 
undesired enantiomer into an achiral amino acid by using an enantioselective oxidase.  
Depending on enantiomer of interest, it is possible to oxidize different orientation as both D and 
L amino acid oxidases are available.  Later, the achiral amino acid can be reduced into a racemic 
mixture through a chemical reduction. Alexandre et al. discussed the advantage of using amine-
boranes for this purpose as less initial material is necessary to achieve the reduction (Alexandre 
et al., 2002). Additionally, models to predict and enhance the performance of this cyclic 
stereoinversions have been developed (Findrik et al., 2005; Kroutil et al., 1998). As mentioned 
before, these processes require the utilization of reduction agents. Therefore, process cost-
effectiveness will be linked to the price of substrate vs. reducing agents. 





Crystallization is one of the predominant techniques for the resolution of chiral compounds 
because of its robustness, simplicity, and cost effectiveness (Lorenz et al., 2014). As any 
crystallization process, separation of enantiomers it is driven by supersaturation at some 
conditions. However, the similarity of the enantiomers introduces complexity, as enantiomers are 
mirror images compounds that exhibit the same physical and chemical properties.  
The vast majority of enantiomeric compounds are categorized as conglomerates 
or racemic compounds forming systems (Eliel, 1983). Ternary phase diagrams of such 
systems are illustrated in Figure 1 where solubility curves are presented at two different 
temperatures (i.e. two superimposed phase diagrams). 
 
             Figure 2.5:  Conglomerate-forming (left) and racemic-compound-
forming (right) systems. 
Vertices of the triangles represent pure components with solvent at the top and the enantiomers 
at the bottom. The sides of the triangle represent the solvent-enantiomer or enantiomer-
enantiomer systems. In both diagrams, Zone 1 represents undersaturated solutions; Zones 2 and 3 
correspond to saturated solutions in equilibrium with enantiomerically pure crystals; Zone 4 
represents saturated solutions in equilibrium with a physical mixture of crystals of the 





system is Zone 5, which has saturated solutions coexisting with crystals of a racemate 
compound. Such crystals incorporate both enantiomers in a single crystal lattice.  
 
Multiple techniques have been developed for the resolution of racemic mixtures (Lorenz 
et al., 2014). One that has been extensively applied for the resolution of conglomerate forming 
systems is preferential crystallization. Preferential crystallization simply refers to the utilization 
of seeds of the desired enantiomer to promote its nucleation over the counter enantiomer.  In 
order to explain the process, let’s assume that the conditions in Figure 2.5 are that the solution is 
supersaturated with respect both enantiomers, but this supersaturation is not enough to induce 
spontaneous nucleation. However, as explained in Section 2.1, at these conditions it is still 
possible to reduce supersaturation through secondary nucleation and/or crystal growth. Hence, if 
a solution is seeded with crystals of some orientation, we can preferentially promote secondary 
nucleation of these crystals. As shown in Figure 2.6, the solution concentration will move 
through a tie line indicating crystallization of a single enantiomer. However, at some point the 
enantiomeric imbalance will be high enough that crystals of the counter enantiomer will nucleate 
and the concentration will move towards equilibrium, which is at the middle of the ternary phase 
diagram. It is therefore necessary to understand crystallization kinetics to optimize this operation 






Figure 2.6: Preferential crystallization process. Red line: Tie line of D-
enantiomer. Blue: Tie line of L-enantiomer. 
 In order to enhance the efficiency of this technique multiple hybrid systems have been 
developed. For example Svang-Ariyaskul et al. developed a system in which membranes and 
crystallization separations were integrated (Svang-Ariyaskul et al., 2012).  The process consists 
of connecting two crystallizers through a membrane that allows migration of the enantiomers 
from one crystallizer to the other. Seeding each vessel with a different enantiomer enables 
preferential crystallization in the vessel. As crystallization of each enantiomer proceeds, their 
respective concentrations will decrease. Hence, in order to maintain chemical equilibrium 
interchange of enantiomers will occur through the membranes.  Elsner et al. developed a similar 
system in which each crystallizer is connected to a shared dissolution vessel that feeds both 
crystallizers with a racemic mixture (Elsner et al., 2009). These processes rely on controlling the 
enantiomeric imbalance so that nucleation of the undesired enantiomer is controlled. As a result, 





enantiomer. Unfortunately, preferential crystallization cannot be applied to racemic compound 
forming systems. Resolution of racemic compound forming systems requires changing the 
thermodynamics of the system via salt formation or enriching the solution respect to the desired 
enantiomer. 
Salt formation was discovered by Pasteur in 1853 and it still is one of the most employed 
processes to obtain optically active crystals. This resolution method consists in the formation of a 
salt between a racemic acid and an optically active base or a racemic base with an optically 
active acid (Eliel, 1983). As shown in figure 2.7, salt formation breaks the symmetry of the 
system, enabling crystallization of a single diastereomers at the middle of the ternary phase 
diagram. Finally, the new salt has to be broken in order to obtain the pure enantiomer from the 
purified diastereomer. Jaques et al. described several methods as decomposition by mineral 
acids, inorganic bases, alumina and ion exchange resins that could be used to obtain the final 
product. 
 
Figure 2.7: Phase diagrams of racemic compounds forming system (left) and 
diastereominc salts of racemic compound forming system (right). 
 
Another technique that can be used to enrich solutions with desired enantiomer is the 





racemic mixture to a chromatographic bed that contains a chiral stationary phase. However, 
classic batch chromatography does not provide high productivities, which inhibits its utilization. 
In order to make the process cost effective the integration of simulated moving beds (SMBs) and 
crystallization had been studied (E. Francotte, 2009; E. Francotte et al., 2002; E. R. Francotte, 
2001). This process consists of alternating the feed and outlet position of the beds, simulating the 
movement of the stationary phase. Such process maximizes the utilization of the bed, increases 
productivity, and enhances the separation. 
2.3 Synthesis and separation of β-lactam antibiotics  
β-lactam antibiotics are the class of antibiotics that contain a β-lactam ring within their 
structure. This group includes a broad range of penicillin derivatives such as ampicillin and 
amoxicillin,  cephalosporins, monobactams, and carbapenems. This type of antibiotic spans 
approximately 65% of the world market for antibiotics, with sales greater than $15 billion per 
year (Elander, 2003; Giordano et al., 2006).  Commercial manufacture of β-lactams antibiotics 
usually is achieved through conventional organic synthesis where low temperatures, 
organochloride solvents,  and protection/deprotection groups are employed (Ospina et al., 1996). 
As a result, significant amount of waste is generated through the process. 
An alternative route for the manufacture of β-lactam antibiotics is the enzymatic synthesis by 
penincillin G acylase (PGA) or amino ester hydrolases (AEH). Although both enzymes can 
performed this reaction PGA had been more extensively used and studied (Blum et al., 2010).  
This enzyme can catalyze the acyl transfer from an activated side chain donor to the nucleophilic 
β-lactam forming the desired antibiotic. For example, the enzymatic synthesis of ampicillin can 
be achieved by reacting 6-aminopenicillanic (6-APA) acid and D-phenylglycine methyl ester (D-
PGME) in the presence of PGA. Similarly, other β-lactam can be produced by PGA simply by 





As mentioned in chapter 1, PGA not only catalyzes the synthesis of ampicillin but it can also 
catalyzes the hydrolysis of D-PGME to D-phenylglycine and the hydrolysis of ampicillin to D-
phenylglycine and 6-APA. In fact, the production of 6-APA can be achieved through hydrolysis 
of penicillin G by PGA (Abian et al., 2003).  Hence, this system is a kinetically controlled 
reaction where ampicillin is an intermediate within the network. Multiple reaction engineering 
strategies had been used to improve the yield of 6-APA towards ampicillin. These strategies can 
be classified into thermodynamically controlled reactions or kinetically controlled reactions. The 
first one relies on medium optimization to shift the microscopic reversibility of the enzymatic 
reaction towards the synthesis reaction. Based on the fact that the undesired reaction is a 
hydrolysis reaction, organic co-solvents have been used to shift equilibrium towards synthesis 
(Abian et al., 2003; Illanes et al., 2002; Kim et al., 1996). This approach has been demonstrated 
to improve the equilibrium constants, but the kinetics and yield of reaction are drastically 
reduced. A different approach relies on optimization of reaction kinetics to enhance the synthesis 
of ampicillin.  
Multiples studies have been done in order to understand the mechanisms of the synthesis of 
β-lactam antibiotics by PGA (Giordano et al., 2006). Youshko et al. work was used to describe 
the complexity of this reaction by considering multiple possibilities of enzyme-substrate-product 
interactions (Youshko, Chilov, et al., 2002; Youshko & Svedas, 2000). Their minimal kinetic 
model demonstrated that synthesis of ampicillin proceeds through the formation of an 
acylenzyme-nucleophile complex. This complex has two potential routes of product unbinding. 
In the first one, the nucleophile and primary hydrolysis products are released as independent 
products (6-APA and D-phenylglycine), while in the second one the antibiotic is released as a 





a different direction. This can be explained as enzymatic microscopic reversibility since binding 
and unbinding can occur in both directions. 
Reactor design and optimization of the synthesis of ampicillin has been an area of extensive 
research (Elander, 2003). Ospina et al. investigated the effect of pH on the synthesis of 
ampicillin by PGA. Ferreira et al. investigated the utilization of non-conventional reactor design 
towards the synthesis of ampicillin (Ferreira, 2007). In their work, a fed-batch with gel matrix for 
enzyme immobilization was utilized. In this wok, high concentrations of substrate enable 
precipitation of ampicillin, but D-phenylglycine was also present in the solid phase. In a similar 
work, Youshko et al. developed a semi-batch reactive system in which D-phenylglycine methyl 
ester was feed at multiple points through the reaction (Youshko et al., 2001). This maximized the 
substrate utilization as the rate of primary hydrolysis was controlled by maintaining relatively 








Reactive crystallization of selected enantiomers: chemo-enzymatic 




 As mentioned in Chapter 2, the different thermodynamic regions indicate that is 
necessary to maintain the solution with an enantiomeric excess greater than the one at the 
eutectic point if an enantiomerically pure crystal is desired (Eliel, 1983). This can be assured 
only if the solution from which the crystals are formed has a solution concentration within the 
boundaries of either Zone 2 or Zone 3 of Figure 2.4. Accordingly, solutions of racemic mixtures 
must be enriched in the desired enantiomer beyond the eutectic point in a supersaturated 
solution; in other words, the enantiomeric excess (ee) must exceed that at the eutectic (eeEu), 
where    L D L Dee 100%  x x x x     and xD and xL are mole fractions of the D and L 
enantiomers. In recognition of these requirements the present work has the following objectives: 
1. Formulate a strategy for chemo-enzymatically enriching an initially racemic mixture in one 
enantiomer at the expense of the other. The enantiomeric enrichment must be accomplished 
at solution compositions appropriate for subsequent crystallization of the desired 
enantiomer.  
2. Demonstrate the feasibility of the strategy on two amino-acid systems: methionine and 
phenylalanine.  This will require several intermediate steps: 
a. Appropriate equilibrium data and models for the two systems must be obtained so that 






b. Identify an appropriate enzyme and test its effectiveness at the temperatures and high 
solute concentrations essential to the success of the strategy. Use the enzyme with the 
two model systems to obtain data sufficient for development of a model for the reaction 
kinetics. 
c. Perform cooling crystallization experiments to verify that crystals of high enantiomeric 
purity can be obtained. Use the data from in situ measurements of solute concentrations 
during crystallizations to obtain rudimentary models of nucleation and growth kinetics. 
d. Combine the models of reaction and crystallization kinetics to demonstrate how these 
two steps can be sequenced to produce the desired isomer.  
e. Use the two-step model to show how the productivity of the process can be enhanced 
through initiating crystallization while enzymatic enrichment is occurring.   
Figure 3.1 is a visual representation of the objectives of the present work. The 
required equilibrium data (Objective 2a) is illustrated in Figure 3.1. This can be 
summarized as obtaining the solubility of the enantiopure compound and the racemate as 
a function of temperature and enantiomeric excess, and the enantiomeric excess at the 
eutectic points along its temperature dependence.  Step 1 shows how the system 
composition is to be adjusted by enantiomeric enrichment (Objective 2b) using specific 
chemo-enzymatic stereoinversion reactions. Demonstration of enzyme stability in 
supersaturated solutions is a major challenge to the success of Step 1, and we show 
experimentally how this challenge was met. In Step 2, the temperature of the system is 
reduced to crystallize the desired product of the reaction (Objective 2c). We describe 
experiments demonstrating the success of Steps 1 and 2 and also formulate models of 





which have not been refined, we show how they can be combined with equilibrium behavior to 
develop a sequential two-step process (Objective 2d) and a process in which reaction and 
crystallization occur simultaneously (Objective 2e), which is illustrated in Step 3 of Figure 2. 
The actual path followed in Step 3 depends on the specific temperature vs. time relationship 
followed, and we illustrate the effect of multiple temperature profiles on the productivity and 
enantiomeric purity of the desired crystals. 
 
Figure 3.1: Reactive crystallization process. At 1 a reaction transforms D into L 
enantiomers, then at 2 the crystallization takes place reducing L-enantiomers concentration. 3 
represents a reaction-crystallization rourte where both reaction and crystrallization occur 
simultaneusly. 
 
3.2 Materials and Methods 
3.2.1 Chemicals and analytical methods 
DL-phenylalanine, DL-methionine, ammonia borane complex, potassium phosphate 
monobasic and dibasic, bovine serum albumin, porcine kidney catalase, and flavin adenine 





purification. Porcine kidney D-amino acid oxidase (D-AAO) was purchased from 
Calzyme Inc. (San Benito, CA). 
The concentration of each of the enantiomers was determined by a Shimadzu 
(Kyoto, Japan) high-pressure liquid chromatography system using a Chirex 3126 (Length 
150 mm, particle size 5 µm, and internal diameter 4.6 mm) from Phenomenex (Torrance, 
CA) and an Astec Chirobiotic T  (250 mm, particle size 5 um, and internal diameter 4.6 
mm) from Sigma Supelco (St. Louis, MO) chiral columns. Calibration curves were 
prepared using both internal and external standards. A polarimeter and a refractometer 
were used during the crystallization experiments. Calibrations of both instruments were 
obtained by measuring the specific optical rotation and refractive index as functions of 
the solution composition. 
3.2.2 Chemo-enzymatic stereoinversion 
Chemo-enzymatic stereoinversion of D-amino acids using D-AAO and ammonia 
borane were used to enrich racemic solutions of DL-phenylalanine and DL-methionine 
into their respective L-amino acids. These amino acids had shown a high degree of 
activity and enantioselectivity with D-AAO towards their respective imino acids [11]. 
The reactions were performed in a 100-mL jacketed reactor in which the temperature was 
maintained at 37 °C by a recirculating water bath. Potassium phosphate buffer (0.1 M) 
was used to maintain the pH at 7.5, which was selected based on the literature [12].  
Flavin adenine dinucleotide was added because it is the cofactor of D-amino acid 
oxidase, catalase was used to decompose hydrogen peroxide, and bovine serum albumin 





by adding 1 mL of a concentrated enzyme solution to saturated or supersaturated solutions of the 
racemic amino acids.  
3.2.3 Solubility 
The solubilities of L- and DL-phenylalanine were determined through isothermal 
experiments at multiple temperatures and compositions.  This was performed by adding an 
excess of the desired compound at a specific enantiomeric excess to water and allowing the 
resulting slurries to equilibrate at the desired temperature for at least 24 h. Samples of solution 
were withdrawn with a syringe through a 0.45 m filter to ensure that only the liquid phase was 
analyzed. Sequentially withdrawn samples were analyzed to ensure that equilibrium was 
achieved.   
3.2.4 Crystallization kinetics 
We developed a monitoring system to obtain crystallization kinetics for the batch 
operation. It consisted of a 500-mL jacketed vessel in which the temperature was controlled by a 
recirculating water bath. A small stream was withdrawn continuously from the vessel through a 
0.1-m filter by a peristaltic pump that circulated the solution through tubing to a polarimeter 
and refractometer in series and then back to the reactor. Temperature-controlled heating tape was 
wrapped around the tubing to prevent crystallization in the lines. The optical rotation, refractive 
index, and temperature were stored as a function of time in a computer.  Prior starting each 
cooling phase, the temperature was raised (5 °C) to ensure crystals dissolution. The L-methionine 
cooling crystallization experiments were performed starting at approximately 40 °C and cooling 
the solution to 20 °C at rates of 0.06 °C/min and 0.1 °C/min. In the case of L-phenylalanine, the 
temperature range was from 35 °C to 15 °C with a cooling rate of 0.1 °C/min. Since the rates of 





refractometer or the polarimeter) was enough to obtain the concentration of the amino 
acid in solution. However, when both enantiomers of a given system are present in 
solution (as when the reactive crystallization is taking place), both the refractometer and 
the polarimeter are necessary to determine the concentration of each enantiomer.   
3.2.5 Crystal recovery  
After reaching a high enantiomeric excess (i.e. where the ee > eeeutectic) using the 
reaction network described in Section 3.2.2, the solution was cooled from 37 °C to 10 °C 
to crystallize the desired enantiomer. While this recovered the desired enantiomer, we 
decided to increase the yield by first isothermally evaporating approximately 15% of the 
solvent, which, of course, increased the concentration of the amino acid in solution. The 
solution was then cooled 10 °C to bring about crystallization of the desired enantiomer.  
Finally, the crystals were recovered by microfiltration through a 0.45 µm filter and then 
redissolved in deionized water for HPLC analysis. 
3.3 Results and Discussion  
3.3.1 Solubility 
 The solubilities of  L- and DL-phenylalanine were measured in the range of 10 °C to 60 °C, 
while the solubilities of L- and DL-methionine were obtained from the literature (Polenske et al., 
2009) .  Both sets of data were fit using a Van’t Hoff equation 




                                                              (3.1) 
with the results shown in Figures 3.2a and 3.3a; values of the parameters A and B for each species 
are reported in Table 3.1. 
The solubility at the eutectic point represents the total solute in solution, and it can be 





approximations developed by Klussmann et al.(Klussmann et al., 2006). In that approach a 
parameter (η) defined as the ratio of the solubility of the racemate compound to that of the pure 
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The left axis of Figures 3b and 4b shows the measured solubilities of the enantiopure compound 
and racemate, and the calculated solubility at the eutectic point (Equation 3.3). In the right axis 
of theses plots, the calculated enantiomeric excess at the eutetectic point is presented (Equation 
3.4). Based on the proximity of the calculated solubility and enantiomeric excess with the 
experimental data reported by Polenske and Lorenz (Polenske et al., 2009), we used the values 





























































Figure 3.2: (a) Solubilities of L- and DL-methionine. (b) Solubilities of L- and DL-
methionine, solution concentration at the eutectic point (experimental and calculated by 
Equation 3.3), and the enantiomeric excess at the eutectic point estimated from Equation 







































































Figure 3.3: (a) Solubilities of L- and DL-phenylalanine, solution concentration at 83% ee. (b) 
Solubilities of L- and DL-phenylalanine, and the ee at the eutectic point estimated from Equation 
3.4. 
 
Table 3.1: Parameters obtained from fitting solubility data for methionine and 
phenylalanine to the Van’t Hoff equation (Equation 1). 
 A(103)  B R2 
DL-Phenylalanine –1.1353 –2.3396 0.9698 
L-Phenylalanine –1.3650 –1.2573 0.9956 
DL-Methionine –2.2721 2.0758 0.9982 
L-Methionine –1.5500 0.1899 0.9892 
 
Finally, since the solubilities are to be used in extensive modeling described later 
in the manuscript, they were correlated as functions of temperature and enatiomeric 
excess (ee) using the following equation: 
   
22S eeC DT ET F                                               (3.6)  
where [S] is the solubility of either the pure L enantiomer or the racemate DL compound. Table 
3.2 provides the parameters obtained by fitting the equation to the available data.  
 
Table 3.2: Parameters obtained from fitting solubility data for methionine and phenylalanine 
to Equation 3.6. 
 C D E F R2 
DL-Phenylalanine 13.460 2.166  10–3 7.932  10–2 4.111  10–3 0.964 
L-Phenylalanine 27.850 –9.593  10–4 2.276  10–1 3.632  10–3 0.997 
DL-Methionine 10.080 4.106  10–3 6.620  10–1 8.290  10–3 0.971 
L-Methionine 54.900 –2.295  10–3 9.024  10–1 2.679  10–3 0.994 
 
3.3.2 Chemo-enzymatic stereoinversion 
Chemo-enzymatic stereoinversions of phenylalanine and of methionine were 





D-AAO oxidizes the D-amino acid in the mixture to the achiral imino (AI) acid, which is then 
then reduced by the reducing agent (RA) ammonia borane to a racemic mixture of the original 
amino acid (Alexandre et al., 2002; Soda et al., 2001) 
 
Figure 3.4: Reactions for chemo-enzymatic stereoinversion. 
Since the first reaction is selective for the D enantiomer, the combination of both 
reactions enriches the solution in the L-enantiomer by consuming two units of D and producing 
one unit of D and one of L. Undesired oxidation of the achiral imino acids to keto-acids is 
possible (Alexandre et al., 2002), but our experiments determined that  maintaining a high 
concentration of ammonia borane (4 mol ammonia borane/mol DL-amino acid) suppressed such 
oxidation and enhanced the rate of reduction of the imino acids to amino acids.  
Racemic supersaturated solutions of phenylalanine and methionine at 37 °C were 
subjected to the stereoinversion reaction scheme. The resulting data shown in Figure 6 illustrate 
one of the key features of the present work: namely, the feasilibilty of performing the reactions at 
supersaturated conditions. As far as we know, the present work is the first example where this 
has been demonstrated. Moreover, the concentrations of both D-phenylalanine and D-methionine 
are shown to approach extinction, demonstrating that high enantiomeric excesses of the L 
enantiomers can be achieved. Therefore, the solution can be moved from Zone 5 to Zone 2 of 





As expected, the concentrations of D and L amino acids in Figure 6 move in 
opposite directions; the concentration of D is decreased due to oxidation while the 
concentration of L increased as it was formed by the reaction cycle. In a perfect execution 
of the reaction cycle, the increase in L would be a reflection of the decrease in D. While 
this was approximately true for the phenylalanine data in Figure 6(a), it was not for the 
methionine data in Figure 6(b). We attribute this lack of symmetry to the system being 
deficient in ammonia borane, which limited the reduction rate of the achiral imino acid 
into L-methionine. Nevertheless, it was still possible to recover enantionmerically pure 
L-methionine from the reaction products because the intermediate imino acid was more 
soluble than methionine.   
Assuming the reactions in Figure 3.4 follow a Michaelis-Menten mechanism, the 
rate of reaction (v) can be described by Equation 3.7. Assuming this model, it is easy to 
show the advantage of performing the reaction at supersaturated conditions, provided 
there is enzyme stability at these conditions. At high values of the substrate 
concentration, i.e. [S] >> KM,  the rate of reaction is maximized at max.  
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Figure 3.5: Chemo-enzymatic stereoinversion of (a) phenylalanine and (b) methionine. Lines 
show linear fits to D-amino acid concentration. (Note: The increase in L-methionine production 






The rates at which concentrations of the D enantiomers decreased were 
determined from the data in Figure 3.5. The consumption of D-phenylalanine followed 
the zero-order kinetics embodied by the approximation in Equation 3.7, but this was true 
only early in the process for D-methionine. Even so, the data for both systems were 
linearized and used to estimate the specific (i.e. normalized by enzyme mass) reaction 
rate constants of phenylalanine and methionine. These were found to be 10.6 and 10.7 
mM/(min∙g enzyme), respectively. The methionine reaction was performed using a 
higher concentration of enzyme, which ris why D-methionine was consumed faster than 
D-phenylalanine even though that the reaction rate constants are similar. 
The observable rates of oxidation determined during our experiments are similar 
to those reported by the manufacturer (Calzyme Inc.) and others (Findrik et al., 2005) for 
the oxidation of amino acids by D-amino acid oxidase. However, overall conversions of 
the D-amino acids into L-amino acids involves both oxidation and reduction.  Since we 
found that the rate of generation of L-phenylalanine tracked the consumption of D-
phenylalanine by oxidation and because the rate of reduction can be increased by 
increasing the concentration of ammonia borane, we assumed in our subsequent analyses 
that the rate of oxidation was the controlling step in the process.  
Table 3.3 lists the parameters obtained by fitting the concentration of D-amino acids as a 
function of time, where the rate of reaction constant (kD) was approximated from the slope and 
the Michealis constant (KM) from the literature (Findrik et al., 2005).  This rate of reaction 
constant is factoring in the fact that for every 2 moles of D-amino acid consumed, one mol of L-





with D-methionine as the substrate was obtained from the literature (Massey et al., 1966) and 
assumed to be the same for D-phenylalanine. 
Table 3.3: Rate of reaction of D-methionine and D-phenylalanine by D-AAO. 
 
 D-methionine D-phenylalanine 
kD (mM∙min-1∙g Eo-1) 10.7 10.6 
KM (mM) 2.5 2.5 
EA (kJ/mol) 38.2 38.2 
R2 0.95 0.98 
3.3.3 Crystallization kinetics 
Enantiomerically pure reaction products were crystallized as described in Section 3.2.5. 
For both the phenylalanine and the methionine systems, the crystals obtained had chemical and 
enantiomeric purities over 99% . In fact, HPLC analysis of the recovered crystals was unable to 
detect reaction by-products or opposite enantiomers. These results demonstrate the feasiblity of 
performing the reactions at crystallization conditions (i.e. in supersaturated solutions) and of 
recovering enantiomerically pure crystals from the reaction products. 
The rates of crystallization of L-phenylalanine and L-methionine were determined 
experimentally by coupling solute and population balances through the method of moments 
(Randolph et al., 1988)where moments of the population density function are given by 
 
0
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                                                                   (3.8)                                                                       
The zeroth, first, second, and third moments are related to the total number, length, area, and 
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where B and G are respectively the nucleation and growth rates. Kinetic expressions for 
nucleation and growth were expressed as  
 satB [ ]] [
b
B k L L                                                            (3.11)                                                                      
 satG [ ]] [
g
G k L L                                                          (3.12)                                                                                                                        
where kB, kG, b, and g are system-dependent parameters.  Finally, a solute mass balance gives 
  3
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where c is crystal density (set at 1000 kg/m3) and kv is the volume shape factor (set at 0.1), 
which are approximated based on  the fact that the particles are elongated but do not affect 
significantly the simulation outcome. 
The concentrations of enantiomers during batch operations must be known to 
estimate the rate of crystallization. This was achieved using a monitoring system similar 
to that of Rodrigo et al. (Rodrigo et al., 2004); as described earlier, the solution was 
withdrawn, circulated through a polarimeter and a refractometer, and returned to the 
crystallizer. Concentrations of both enantiomers in the crystallizer were determined using 
appropriate calibrations of the two instruments. The measured temperature was combined 
with the solubility models developed Section 3.3.1 to estimate the solubility during a run.  
Finally, the experimental concentration was compared to that calculated from the mass 
balance in Equation 3.13.  
Estimation of parameters in the kinetic expressions was performed using the 
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where xi(t,p)  represents the modeled concentration at some set of parameters p = [kb b kg g], 
exp
( )i tx  
represents the set of concentrations determined experimentally, Nx  is the number of data points, 
and Nexp the number of experiments.  (For methionine Nexp = 2 and for phenylalanine Nexp = 1.) 
The probability of being trapped in a local minimum was reduced by performing two consecutive 
minimizations. First, a stochastic minimization (MATLAB simulannealbnd) was used to identify 
the best set of parameters among multiple combinations of parameters. Then, that set of 
parameters was used as the starting point of a deterministic minimization (MATLAB fminsearch) 
that refined the parameters and further reduced the error. 
The robustness of the identified set of parameters was quantified by the confidence 
interval of each parameter calculated using the recommendation of Nagy et al. (Nagy et al., 
2008). The confidence intervals of the parameters obtained were narrow, which means that the 
estimated set of parameters provides a good approximation of the true set. However, these 
confidence interval are based on concentration data which is easier to fit than CSD or moments 
data. Is expected that if particle information is included, the confidence intervals should be much 
broader.  Results of the fitting procedure are given by the parameters in Table 3.4. As expected, 
nucleation exponent are large since the empirical equation is capturing primary nucleation. It is 
important to notice that these parameters were estimated from concentration data, and they 
should only be used accordingly. Estimations of crystal size distribution would require including 
CSD data in the parameter-estimation procedure. However, since the purpose of the present work 
is focused on the mass of species produced and not CSD, the estimated parameters are sufficient 









Table 3.4: Parameters used to model crystallization kinetics. 
Parameters L-methionine L-phenylalanine 
kB  (#/(g/kg)b∙min) 2.03  108 ± 5.72  106 7.08  105 ± 2.32  104 
b 12.21 ± 0.14 7.56 ± 0.12 
kG (m/(g/kg)g∙min) 4.86  10–8 ± 9.17  10–10 1.99  10–7 ± 6.07  10–9 
g 0.67 ± 0.01 1.36 ± 0.03 
 
Comparisons between experimental concentrations at run conditions given in Section 
3.2.4 and those obtained from the fitting procedure are shown in Figures 3.6 and 3.7. Clearly, the 
fit to each data set is satisfactory as the corresponding model describes the change in solute 
concentration during the course of a run and, by mass balance, facilitates prediction of the yield 
of each species. Again, however, we point out that the parameters were estimated using solute 







































































Figure 3.6:  Experimentally determined and modeled concentration profiles of L-
methionine for batch cooling crystallizations at two different cooling rates, (a) 0.10 




































Figure 3.7:  Experimentally determined and modeled concentration profiles of L-phenylalanine 
for batch cooling crystallization at a cooling rate of 0.1 °C/min. 
 
3.3.4 Process modeling 
In the previous sections we demonstrated and modeled the elements of the process 
proposed for the separation of enantiomerically pure isomers from racemic mixtures. To 
recap the two key steps of the process:  (1) chemo-enzymatic stereoinversion to enrich 
the concentration of one of the enantiomers in an originally racemic mixture so that the 
solution composition is relocated to Zone 2 of Figure 1(b) ; (2) crystallization of the 
desired enantiomer from the solution formed by chemo-enzymatic stereoinversion. Such 
steps represented in Figure 2 as 1 and 2, were determined experimentally in Section 3.3.2 
(Figure 3.5) and 3.3 (Figure 3.6 and 3.7). In this section, we show that the separately 





combined model can be used to guide optimization of the process.  This model is used to 
simulate the path named 3 in Figure 3.1, where different routes in which reaction and 
crystallization occur simultaneously are explored. 
We first show how to combine the solids formation described by crystallization kinetics 
with mass balances on D and L enantiomers, the reducing agent RA, and the achiral imino acid 
AI involved in the reaction cycle shown in Figure 3.4. The species balances are given by 
   
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         o oAI = D + L D L                                             (3.18) 
where the rate of oxidation of L-amino acids (ko,L) has been set to zero. 
Analytical solutions for similar models are discussed elsewhere, but combining these expressions 
with crystallization kinetics results in a set of stiff differential equations. Since none of the stiff 
differential-equation solvers in MATLAB (ode15s, ode23s, and ode23tb) gave accurate solutions 
to the equations, we simplified the reaction kinetics and combined the results with crystallization 
kinetics to design the reaction-crystallization operation.  
In the following approach, we assumed that the chemo-enzymatic stereoinversion occurs 
in a single reaction for the direct conversion of D-amino acids into L-amino acids; in other 
words, we ignore the intermediates AI and other reactants RA. Such an approximation is justified 
if RA is in excess (i.e. [RA] is large) and if [AI] is minimized by enhancing the rate of reduction. 





conversion of D-amino acids, represented by the net rate of reaction constant (kD).  
Notice that the mechanism of the reaction works in a way that for every 2 moles of D-
amino acid, only one is converted into L-amino acid and the other one into D-amino acid. 
Additionally, an Arrhenius expression is used to take into account the decay of the rate of 
reaction during the cooling phase. 
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Rates were estimated as discussed in Section 3.3.2, and modeling the effect of 
temperature was needed to account for the reaction-rate reduction during cooling, which 
occurs when crystallization and reaction are combined. By coupling the solids balance 
(Equation 3.13) and with the balance on L (Equation 3.19), we obtain 
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The resulting system of differential equations was solved in MATLAB by a stiff ordinary 
differential equation solver (ode15s). 
The validity of the modeling approach was tested by comparing predictions of the 
combined model with segments of experimental data on each of the constituent steps in the  
process; in other words, the model was initiated at the same temperature and concentration as the 
experiment reported in Figure 3.5(a) and allowed to proceed until enrichment in L-phenylalanine 





took approximately 600 minutes. At that point, cooling was initiated and followed the protocol 
for the experiment in Figure 3.7. The two sets of experimental data (one for reaction, the other 
for crystallization) are shown in Figure 3.8 along with the model predictions. In other words, 
during the first 600 minutes the model is compared against reaction data at the same conditions, 
and from 600 to 1200 minutes crystallization data is compared against the model using the same 
temperature profile. It can be seen that the model does fit both the reaction section (first 600 
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Figure 3.8:  Experimental and modeled crystallization 
concentration profiles of L-phenylalanine. 
 
Given the success of the model in reproducing system behavior, it was used to examine 
the effects of different cooling strategies on the productivity and enantiomeric purity of the 
recovered crystals. For example, consider the illustration of a base case in Figure 3.9. Here the 





consumed and then the system temperature was reduced at a constant rate of 0.1 °C/min. 
Note how the concentration of the desired L enantiomers increased from the initial 
racemic conditions while concentrations of the D enantiomers fell to zero. Then, as 
crystallization began, the concentration of the L enantiomer in solution decreased in 
correspondence to the increase in L enantiomer crystals. Also note that there is a 
substantial period of time when there is little change in the system concentrations: 
between 300 and 600 minutes for phenylalanine and between 600 and 800 minutes for 
methionine. These base cases represent the path composed by steps 1 and 2 in Figure 3.1. 
We now use the model to simulate processes that follow a reaction crystallization route 
(as path 3 on Figure 3.1) and to demonstrate how the overall process can be made more 

















































































A series of simulations were performed with identical cooling rates between 
identical initial and final temperatures, but with different times at which cooling was 
initiated. The initial temperature of the reaction mixture was maintained high at the 
beginning of the process so as to enhance the rate of the stereoinversion, but then 
decreased to crystallize the desired enantiopure amino acid. If cooling is initiated too 
soon, crystallization of the racemate or co-crystallization of the racemate and enantiopure 
compound will take place.Figure 3.10 shows accumulations of crystals of pure L-
phenylalanine for initiation of cooling at various times. In all of these runs, the 
production of DL-phenylalanine was miniscule and could be ignored, indicating the 
preferred operation would initiate cooling so that the overall run time was minimized. For 
the results in Figure 3.10, that would correspond to initiating cooling after about 200 








































Figure 3.10:  Accumulation of L-phenylalanine crystal mass when initiating 





Simulations similar to those described for phenylalanine were also performed for 
methionine and gave a significantly more complicated outcome, as shown in Figure 3.11. The 
figure shows that is some runs both L- and DL-methionine were produced. Note that the curves 
for 100 minutes are for both enantiomers, and DL-methionine is produced in significant 
amounts, starting at about 200 minutes; on the other hand, essentially no L-methionine is 
produced until around 1100 minutes. These results demonstrate that initiating cooling prior to 
inadequate enrichment by stereoinversion leads to crystallization of the undesired racemic 








































Figure 3.11:  Accumulation of L- and DL-methionine crystal mass when initiating 






The different cooling profiles shown in Figures 3.10 and 3.11 were evaluated by 
calculating a process productivity based on the total amount of crystals obtained at a 




P                                                                 (3.23) 
The total elapsed run time is t and [L]solid is the mass of enantiopure crystals per unit mass of 
solvent.  
Figures 3.12(a) and 3.13(b) show, respectively, the productivities of L-
phenylalanine and L-methionine at multiple cooling profiles that led to high enantiomeric 
excesses of the desired products. There is a clear maximum in each of the productivity 
plots, which represents the most efficient use of the system; at times beyond the maxima, 
productivities decrease since the yield of crystals remains essentially constant. Moreover, 
comparison among the protocols for each solute demonstrates superiority of one over the 
other; i.e. for L-phenylalanine the most productive protocol has cooling being initiated 
200 minutes after the process was started, while the most productive for L-methionine 









































































Figure 3.12:  Productivity of enantiopure crystals under varying cooling protocols: (a) L-





 Finally, we considered the effect of cooling rates on the progress of the crystallization 
component of the process. We did this by choosing the two favored times for initiating cooling 
(200 minutes for phenylalanine and 400 minutes for methionine) and varied the constant rates of 
cooling from 0.1 °C/min to 0.4 °C/min. Figures 3.13(a) and 3.13(b) show the results for 
phenylalanine and methionine and illustrate that the productivity of phenylalanine crystals can be 
enhanced, without compromising crystal purity, by using a cooling rate of 0.2 °C/min but 
increasing the cooling rate for methionine led to a decrease in productivity, probably because 








































































Figure 3.13: Effects of cooling rate on productivity of enantiopure crystalline 
products: (a) L-phenylalanine with cooling initiated at 200 minutes; (b) L-methionine 





The previous simulations show the potential advantages of performing parallel chemo-
enzymatic reactive crystallization operations. The results demonstrated how different cooling 
profiles affect the productivity of crystals and their enantiomeric purity. It is expected that 
optimization of this reaction-crystallization process could further improve the productivity of the 
operation since the optimal temperature profile might not follow a linear profile and the cooling 
stage could start between any of the initial times tested in this set of simulations. 
 
3.4 Conclusions 
We link the conclusions drawn from our work to the objectives described in the 
Introduction. First and foremost we have formulated and demonstrated an effective 
strategy for producing enantiomerically pure species from racemic mixtures of racemate-
forming amino acids. The strategy uses chemo-enzymatic stereoinversion to enrich the 
desired enantiomer in initially racemic solutions. Enrichment was shown to adjust the 
solution composition so that it was moved to a region of the phase diagram that ensured 
crystallization of the desired enantiomer.  
Each element of the strategy was investigated experimentally; i.e. we successfully 
demonstrated that racemic mixtures of phenylalanine and methionine could be enriched 
in their respective L enantiomers using a reaction cycle that moved solution 
concentrations to zones where the L enantiomers could be crystallized without 
contamination by the DL racemate. The experiments included measuring or otherwise 
obtaining phase-equilibrium data for the two model systems, verifying that the enzyme 
critical to the stereoinversion could be used at the high solute concentrations essential to 
the success of the process, testing that crystallizations at process conditions resulted in 





stereo inversion and for crystallization that could be used in modeling the combined process.    
Simulations based on the models developed from our experiments showed the potential 
advantages of coupling chemo-enzymatic reactions and crystallization to resolve racemic 
mixtures of amino acids. The results show that the key feature of this operation is the reduction 
of the total time of the operation, which enhances the productivity of the process.   
Although the data and simulations were for phenylalanine and methionine, the strategy 
developed has broader potential and may be found useful in other high-value systems where 







Generic Dynamic Optimization for Reactive-Crystallization of Chiral 
Compounds 
4.1 Introduction 
Crystallization is a widely used for the separation and purification of specialty chemicals and 
pharmaceutical compounds. However, even though crystallization has been used in multiple 
industries during the past century, systematic approaches for the design of efficient 
crystallization-based operations has been discussed recently. For example, Wibowo et al. 
discussed the integration of crystallization in downstream processing (Wibowo et al., 2001). In 
their work, the effect of crystallization on other operations such as filtration, washing, 
dewatering, re-crystallization, and drying was studied.  As expected, crystal size distribution 
(CSD) played an important role on the efficient integration of crystallization and these other 
operations. Schroer et al. and Berry et al. used a systematic approach to design reactive 
crystallization operations (Berry et al., 1997; Kelkar et al., 1999). In their work, information 
about reaction and crystallization kinetics is used for to design upstream-downstream operations.   
In this work, a general scheme for the dynamic optimization of reactive-crystallizations is 
presented. The idea is to select an optimal temperature profile that benefits both upstream 
(reaction) and downstream (crystallization).  As a result, the productivity of the operation can be 
enhanced. This is illustrated by performing an optimization of a reactive crystallization towards 
the production of enantiomerically pure compounds from racemic mixtures. Chiral compounds 
exhibit the same chemical and physical properties. Hence, most separation techniques fail on the 
resolution of enantiomers. Although these compounds exhibit multiple similarities, they can 





enantiomerically pure compounds (Schroer et al., 2001). In this chapter, we will use 
experimental information related to solubility, reaction kinetics, and crystallization kinetics to 
develop models that could be used to maximize different performance criteria. 
4.2 Parameter Estimation 
4.2.1 Solubility and Phase diagrams 
The first step on the design of any crystallization-based separations is getting equilibrium 
data. Therefore, solubility data has been obtained for the racemic mixture, enantiopure 
compound, and the solubility at the eutectic point. For simplification purposes, we will assume 
that only the desired enantiomer is going to be crystallized, and its solubility will only depend on 
temperature.  Equation 4.1 was used to model the solubility as a function of temperature, where 
the heat of melting (∆HM), difference in sensible heat between liquid and solid phase (∆CP), and 
melting temperature (TM) were the parameters obtained fitted by an error minimization routine 
developed  in MATLAB.  Figure 4.1 shows the solubility data along with a fitting used to model 
solubility as a function of temperature.  
 
Figure 4.1: L-phenylalanine, DL-phenylalanine, and phenylalanine eutectic point solubility. 
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Table 4.1: L-phenylalanine solubility constants. 
 
mH (J/mol) pC (J/mol·K) Tm (K) 
L-phenylalanine 50327 93 728 
 
Using the previous information, the solubility can be easily estimated if the temperature is 
known. In Section 4.2.4, temperature will be used to estimate the solubility, and therefore, the 
driving force of crystallization. 
4.2.3 Reaction kinetics 
Kinetic models for chemo-enzymatic stereoinversions have been studied before (Kroutil et 
al., 1998; Soda et al., 2001). This reaction proceeds through multiple oxidation-reduction steps, 
in which the undesired enantiomer is transformed into an achiral intermedia and then reduced to 
a racemic mixture of amino acids. However, since the first step is enantioselective, the overall 
“net” reaction is enantioselective. As shown in Figure 4.2, the net effect of the cyclic oxidation-
reduction is the transformation of the undesired enantiomer to its counterpart.  In this example 
we simplified the rate of reaction to first order kinetics, in which the undesired enantiomer is 
transformed to the desired one (i.e. ignoring intermediate steps). By assuming this reaction 
mechanism the observable reaction constant was determined from the slope of the concentration 






Figure 4.2: Chemo-Enzymatic Stereoinversion of phenylalanine at saturated conditions. 
4.2.4 Crystallization kinetics 
Crystallization kinetics was determined through the method of moments. The advantage of 
using this form is that the partial differential equation that represents the population balance is 
transformed to a system of ordinary differential equations. Equation 4.2 shows the definition of 
the moments of a population density function. The different indexes i, represent the different 
moments of the population density. In this case, the zeroth, first, second, and third moments 
represent the total number of nuclei, length, area, and volume of crystals, respectively. The total 
volume of crystals is linked to the mass of crystals by assuming a certain particle density. 
Transforming volume to mass is useful since the mass concentration is easier to quantify than the 
volume of particles. Equations 4.3 and 4.4 represent the rate of change of each of moment, which 
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Finally, by assuming a certain particle density and shape factor we can obtain an expression for 
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This equation was used to estimate crystallization kinetics of L-phenylalanine whose values are 
reported in Table 4.2.  Figure 4.3 shows a desupersaturation plot for L-phenylalanine. The green 
line on the graph represents a solubility cure, while the red (model) and blue (experimental) 
represent concentration profiles. The concentration was measured using an online monitoring 
system in which the solution was recirculated through a polarimeter and a refractometer, and 
solubility was estimated by measuring the temperature and using the model developed in Section 
4.2.1 (Experimental set-up is not discussed in this chapter). 
Table 4.2: Parameters of L-phenylalanine crystallization kinetics 
kB  (#/(g/kg)b∙min) b kG (m/(g/kg)g∙min) g 








Figure 4.3: Cooling crystallization of L-phenylalanine. 
 
4.3 Dynamic Optimization Models 
4.3.1 Reaction and parallel nucleation and growth rate 
The following model represents a reactive crystallization where the reactions is being 
modeled by a first order reaction and crystallization by primary nucleation and growth rate 
kinetics. The fundamental assumption of the model it is that when the solution becomes 
supersaturated, nucleation and growth are going to start simultaneously. Similar models had been 
used in the literature (Kelkar et al., 1999) to design crystallization processes. Equations 4.6-4.8 
represent the mass balance of all the components. Notice, that all the differential equations 
depend on temperature.   
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                                                                 (4.9) 
The optimization criteria selected for this model was time minimization. The idea it is minimize 
the time required to meet a certain yield of the desired enantiomer in the solid phase. 
T T f min   t                                                                (4.10) 

    
dz(t
s.t.  f z t , u t
dt
                                               (4.11) 
f solid[ ](t ) yieldLsolidL                                               (4.12) 
 
Such a formulation will maximize the productivity of the operation since the time required to 
meet certain product specification it is minimized. In this minimization strategy the temperature 
was selected as the control vector (i.e. u(t)=T(t)) and used in the  state equations  z(t) (i.e. 
differential Equations 4.7 to 4.9). This simulation was performed with an initial temperature of 
60 oC, an initial concentration of the racemic mixture of 60 g/kg solvent, and all the moments of 
the distribution were set to zero (i.e. µi (0)=0). The optimization was performed in MATLAB 
using the dynamic optimizer (GPOPs). Figure 4.4 (Left) shows the optimal temperature profile, 







Figure 4.4: Left: Optimal temperature profile. Right: Concentration profiles. 
The behavior of the optimal temperature profile makes sense because at the beginning we want 
to maintain high temperatures to enhance the rate of production of the desired product, and then, 
decrease the temperature to enhance the rate of crystallization. To verify the validity of the 
optimization, a mass balance was used to verify mass conservation through time. The 
verification of mass conservation it is important because crystallization is a very non-linear 
process, and since a collocation method is being used, the polynomial approximation could yield 
an inaccurate mas balance.  Also, to verify optimality, the Hamiltonian was evaluated through 








                                                           (4.13) 
H Constant                                                                  (4.14) 
and since we are trying to minimize tf, this constant must be zero. Figure 4.5 (Left) shows the 
mass conservation profile, while Figure 4.5 (Right) shows the Hamiltonian profile. We can 
notice that mass is roughly conserved, but at the end of the problem the Hamiltonian deviates 


























even more from zero. Most likely, this is due the high non-linearity of the problem, which can 
make quick changes to either the states or the costates. 
 
Figure 4.5: Left: Mass conservation. Right: Hamiltonian evaluation. 
To finalize the analysis of this model, sensitivity on the parameters of the rate of crystallization 
was performed. This is important since during the parameter estimation of the crystallization 
kinetics, multiple solutions (or local minima) were found. Figure 4.6 shows the optimal 
temperature profile for two different values on the rate of nucleation constant kB. We can notice, 
that the behavior of these plots is relatively similar.  
 
Figure 4.6: Temperature profile for kB = 1x10
9#/min (Left) and kB = 1x10
7#/min (Right). 
However, when the nucleation exponent was varied (Figure 4.7), the behavior of the optimal 
temperature profile was completely different. Therefore, if the number of estimated parameter 


























































































must be reduced, the nucleation exponent should be fixed. This would increase the robustness of 
the model and the optimization. 
 
Figure 4.7: Temperature profile for b = 4 (Left) and b = 5 (Right). 
 
4.3.2 Reaction and method of moments 
An alternative model was developed based on the method of moments. In this case, a 
reaction term was included into the mass-based third moment. By doing such a manipulation, a 
model in which nucleation and growth do not start simultaneously can be developed. 
  R o c v 2
dL
k E D 3ρ k Gμ
dt
                                                   (4.15) 
  
Using this model, we can capture other information about the process such as crystal size 
distribution since average properties of the population are being capture. For example, we can 
calculate the mean size or size variance. 
 1 0/avgL                                                                       (4.16) 
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In this model, we consider maximizing the yield of the product and its final mean size. Equation 
4.18 shows the objective function used for this optimization. A weight constant was used to give 
more importance to one objective vs. the other. 
      s f 1 0 fw L t 1 w μ /μ t                                      (4.18)  
If maximizing the yield was heavily weighted, the problem is analogous to the time minimization 
problem. However, in this case, the time is fixed and the yield is maximized. Nevertheless, both 
problem formulations maximize the productivity of the operation. Figure 4.8 shows the optimal 
temperature profile (Left) and the respective mass accumulation profile (Right) using the same 
initial conditions as the problem stated in the previous section. As expected, the temperature is 
maintained high at the beginning and then it is decreased to enhance the rate of crystallization. 
 
Figure 4.8: Optimal temperature profile (Left) and crystals accumulation profile (Right) for the 
yield maximization problem. 
Now we consider reducing the value of w; hence, the problem becomes a multiobjective 
optimization. In this case, we want to maximize both the yield and mean size. Figure 4.9 shows 
the temperature profile (Left) and crystals accumulation (Right). The behavior of this optimal 
temperature profile is not obvious; at the beginning, instead of maintaining the temperature 

















































constant, the temperature is reduced. Probably, by reducing the temperature, the rate of reaction 
is reduced, which reduces the rate of supersaturation build-up. It is well known, that a high 
supersaturation leads to high nucleation rates. Therefore, since we want to maximize the size of 
the crystals, we want to suppress nucleation and enhance crystal growth rate. 
As expected, the amount of crystals recovered from this operation is lesser than the one in which 
only the yield was considered. However, the crystals of this operation would have a bigger mean 
size, which is desirable in downstream processing of solids (i.e. filtration, washing, and 
recrystallizing). Therefore, on each specific example, the importance of size distribution vs. 
productivity must be weighted. In some operations such as recovery of bulk chemicals 
productivity would be a predominant factor, but for pharmaceutical compounds, crystal size 
distribution is a major factor. 
 
Figure 4.9: Optimal temperature profile (Left) and crystals accumulation profile (Right) for the 
multiobjective maximization of yield and mean size. 
4.4 Conclusions 
` In this work, the framework for a dynamic optimization of a reactive-crystallization of 
enantiomerically pure compounds was developed. The results show the possibility of enhancing 














































the productivity of reactive-crystallization operations by selecting an optimal temperature 
profile. One of the key and still unclear issues it is the parameters used in the model. During the 
crystallization kinetics parameter estimation routine, multiple set of parameters were able to fit 
the experimental concentration profile. Nevertheless, if the only focus is maximizing the 
productivity (maximize yield or reduce time) of the operations, any set of parameters might be 
enough (We do not care about distinguishing between nucleation and growth). However, the 
second model was developed using a reactive-method-of-moments. In this case, we wanted to 
maximize the yield and mean size. Therefore, since the mean size is defined using the moments 
(and the respective nucleation and growth parameters), inaccurate prediction on the 
crystallization kinetics will produce an inaccurate temperature profile. Another key point noticed 
was that collocation methods gave inaccurate integrations on some critical points. During the 
onset of nucleation the concentration profiles becomes extremely non-linear and polynomial 
approximations will fail on predicting the concentration. A possible strategy can be adding more 







QUANTIFICATION OF THE EFFECT OF PH AND CONCENTRATION 
ON PGA REACTION KINETICS 
5.1 Introduction 
β-lactam antibiotics are the class of antibiotics that contain a β-lactam ring within their 
structure. This group includes a broad range of penicillin derivatives such as ampicillin and 
amoxicillin, and cephalosporins, monobactams, and carbapenems. These antibiotics span 
approximately 65% of the world market of antibiotics, with sales greater than $15 billion 
(Elander, 2003; Giordano et al., 2006).  Commercial manufacturing of β-lactams antibiotics 
usually is achieved through conventional organic synthesis where low temperatures, 
organochloride solvents,  and protection/deprotection groups are employed (Ospina et al., 1996). 
As a result, significant amount of waste is generated through the process. 
An alternative route for the manufacture of β-lactam antibiotics is the enzymatic synthesis by 
penincillin G acylase (PGA). This enzyme can catalyze the acyl transfer from an activated side 
chain donor to the nucleophilic β-lactam forming the desired antibiotic. For example, the 
enzymatic synthesis of ampicillin can be achieved by reacting 6-aminopenicillanic (6-APA) acid 
and D-phenylglycine methyl ester (D-PGME) in the presence of PGA. Similarly, other β-lactam 
products can be synthesized by simply changing the initial reactants.   
The overall reaction scheme is presented in Figure 5.1. As it can be seen in the figure, PGA 
does not only catalyze the synthesis of ampicillin but it also catalyzes the hydrolysis of D-PGME 
to D-phenylglycine and the hydrolysis of ampicillin to D-phenylglycine and 6-APA. In fact, the 







Figure5.1: Enzymatic synthesis of ampicillin by PGA. 
As it can be observed in the figure, this system is a kinetically controlled reaction, where 
ampicillin is an intermediate within the network. Multiple reaction engineering strategies had 
been used to improve the yield of 6-APA towards ampicillin. These strategies can be classified 
into thermodynamically controlled reactions or kinetically controlled reactions. The first one 
relies on medium optimization to shift the microscopic reversibility of the enzymatic reaction 
towards the synthesis reaction. Based on the fact that the undesired reaction is a hydrolysis 
reaction, organic co-solvents have been used to shift equilibrium towards synthesis (Abian et al., 
2003; Illanes et al., 2002; Kim et al., 1996). This approached demonstrated to improve the 
equilibrium constants but the kinetics of reaction can be drastically reduced.  
In the other hand, optimization of this system is possible by acquiring information about the 
three main reactions: (1) synthesis, (2) primary hydrolysis, and (3) secondary hydrolysis.  
Significant work has been performed in this area including building kinetic models, pH and 
temperature optimization, heterogeneous reactions, and complex reactor design (Ferreira, 2007; 
Youshko, Chilov, et al., 2002; Youshko & Svedas, 2000; Youshko, van Langen, et al., 2002). In 





hydrolysis, and 2o hydrolysis) to understand the predominant factors that influence the selectivity 
and absolute rate of these reactions. Each reaction was carried out in the pH range of 6.0 to 8.0 at 
multiple concentrations to verify their optimal operation.  
5.2 Materials and Methods 
5.2.1 Chemicals 
D-Phenylglycine methyl ester (PGME), 6-aminopenicillaninc acid (6-APA), 
phenylglycine (PG), and ampicillin (Amp) were purchased from Sigma Aldrich USA (St. Louis, 
MO). Potassium phosphates monobasic and dibasic were purchased from VWR USA (Radnor, 
PA). Penicillin G acylase was kindly donated by DSM-Sinochem (The Netherlands). The 
enzymatic solution had a concentration of 17 mg/mL and its purity was verified using a gel 
showing no indication of other proteins.  All the chemicals and enzyme were used without 
further purification.  
5.2.2 Enzymatic Reaction 
The enzymatic synthesis of ampicillin was performed in 10mL test tubes with a working 
volume of 2 mL. The temperature was maintained at 25 °C using a water-bath shaker at 125 
RPM. The reactants were added to the 10 mL test tubes and dissolved using 250mM buffered 
solutions at the desired pH value and adjusting any deviation using hydrochloric acid or 
ammonia. Reactions were started by adding 25 µL of the enzymatic solution. Samples were 
withdrawn as a function of time to construct concentration profiles. 
5.2.3 Synthesis vs. Hydrolysis Reaction 
The initial rates of reaction of synthesis of ampicillin and D-PGME hydrolysis were 
measured at a pH value of 6.00, 6.500, 7.00, and 7.50. The rates of reaction were estimated by 





reaction. The reactions were carried starting with an initial concentration of D-PGME of 50 mM 
and 100mM, while the initial concentration of 6-APA was varied in the range of 10 mM to 300 
mM.  
5.2.4 Primary Hydrolysis Reaction 
The initial rates of reaction of D-PGME hydrolysis were measured at a pH value of 6.00, 6.50, 
7.00, 7.50, and 8.00. The rates of reaction were estimated by measuring the concentration of D-
phenylglycine during the first 30 minutes of the reaction. The reactions were carried starting with 
an initial concentration of D-PGME in the range of 10 mM to 300 mM.  
5.2.5 Secondary Hydrolysis Reaction 
The initial rates of reaction of ampicillin hydrolysis were measured at a pH of 6.0, 6.50, 7.0, 7.5, 
and 8.0. The rates of reaction were estimated by measuring the concentration of ampicillin 
during the first 30 minutes of the reaction. The reactions were carried starting with an initial 
concentration of ampicillin in the range of 5 mM to 50 mM. However, the initial concentration of 
D-PGME for reactions performed at a pH of 6.00, 6.50, or 7.00 was in the range of 5-25 mM 
because the low solubility of ampicillin at these pH values. 
5.2.6 Analytical Methods 
Solution concentrations were analyzed using a Shimazdu (Kyoto, Japan) high-pressure 
liquid chromatography (HPLC) system using an isocratic method at 0.75 ml/min and a 
wavelength of 215 nm. Aliquots of 50 µL where withdrawn using a micropipette and diluted in 
1mL of HPLC solution with 1%v HCl 2M quench the reaction.  The HPLC solution consisted of 
an aqueous solution of 0.68g/L KH2PO4, 0.68g/L SDS at a pH of 3.0 and acetonitrile (70%v 






Calibration curves were performed at a pH of 6.00 and 7.00. This was done to ensure that 
the absorbance of the components was independent of pH value. It was noticed that some peaks 
split when the pH of solution was changed as charged species had a different retention time than 
zwitterions. However, charged and neutral species exhibit the same UV absorbance as a function 
of concentration. 
5.3 Results and Discussion 
5.3.1 Synthesis vs. Hydrolysis Reaction 
To investigate the effect of concentration and pH value on the selectivity of the reaction, an 
experimental design consisting of 6 different concentrations at 5 pH values was investigated. The 
accumulation of ampicillin and D-phenylglycine was tracked and used to estimate the initial 
rates of synthesis and primary hydrolysis. Figure 5.2 shows the accumulation of ampicillin and 
D-phenylglycine at 6 different concentrations of 6-APA while maintaining D-PGME 
concentration constant and the pH value at 6.00. As expected, we can notice that the 
accumulation rate of ampicillin increases as the initial concentration of 6-APA increases. On the 
other hand, accumulation rates of D-phenylglycine decreased as the concentration of 6-APA was 
increased. This demonstrates an increase on selectivity towards synthesis as 6-APA 
concentration increases. Hence, these results suggest maintaining high 6-APA to D-PGME ratios 









Figure 5.2: Initial accumulation of (a) ampicillin and (b) D-phenylglycine at a pH value of 


































































This behavior can be explained using the minimum kinetic scheme (equations 5.1-5.4) developed 
by Youshko et. al.(Youshko, Chilov, et al., 2002) in which the production of ampicillin is a 
function of the concentration of D-PGME and 6-APA. Since the accumulation it is based on 
initial rate experiments, the effect of secondary hydrolysis is negligible as the concentration of 
ampicillin is low. 
2[Amp] [ ][ ] [Amp](1 [ ])
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0[PGME] [ ] [ ] [ ]PGME AMP PG                                       (5.3) 
o[ ] [ ] [AMP]APA APA                                              (5.4) 
Following the same procedure, the reaction was carried at multiple pH values. Figure 5.3 shows 
a summary of the effect of concentration and pH value to the initial rate of synthesis vs. 
hydrolysis.  Figure 5.3 shows that increasing the ratio of 6-APA to D-PGME increase synthesis 
vs. hydrolysis ratios. Such behavior can be modeled by saturation-type kinetics in which the 
selectivity of the reaction is related to 6-APA concentration using Equation 5.5. However, in 
contrast to what was reported in other articles (Youshko, van Langen, et al., 2002), we did not 












                                                 (5.5)  
In Figure 5.3, the effect of substrate ratios to the selectivity of the reaction was fitted  at each pH 
value using liner regressions. The slope of these regressions was used to construct Figure 5.4, 





A comparison of the slope of Figure 5.4 with the slopes of Figure 5.3 indicates that that the effect 
















y = 0.078745 + 1.4954x   R= 0.98275 
y = 0.216 + 1.0526x   R= 0.97016 
y = -0.34448 + 1.1603x   R= 0.97312 































Figure 5.3: Effect of substrate ratio and pH value to the initial synthesis vs. hydrolysis ratios 
for a varying concentration of 6-APA and a constant D-PGME initial concentration of 100 mM. 
 
Figure 5.4: Slopes of the effect of substrate ratio at different pH values. 













































5.3.2 Primary Hydrolysis Reaction 
In order to investigate the effect of concentration and pH value on the rate of primary 
hydrolysis, an experimental design consisting of 6 different concentrations at 5 pH values was 
investigated. The consumption of D-phenylglcyne methyl ester was tracked and used to estimate 
the initial rate of primary hydrolysis. Figure 5.4 shows an example of the hydrolysis reactions, in 
this case D-phenylglycine methyl ester concentration was monitored during the 30 minutes at 
multiple concentrations at a pH value of 7.00 and 298 K. As expected, higher concentrations 
enhances the rate of reaction.
Figure 5.5: Hydrolysis of D-PGME at different initial concentration at a pH value of 7 and 298K. 
Following a similar procedure, the initial rate of reaction was estimated at 4 additional pH 
value values and the results reported in Table 5.1. The results indicate that the rate of reaction 

































Table 5.1: Initial rate of primary hydrolysis v0 (mM min
-1)  at multiple concentrations (mM) and 
pH values. 
 
[PGME] v0 [PGME] v0 [PGME] v0 [PGME] v0 [PGME] v0 
pH 6.0 pH 6.5 pH 7.0 pH 7.5 pH 8.0 
28.73 -0.32 21.34 -0.37 42.63 -1.19 28.1 -1.11 39.32 -1.50 
50.42 -0.19 46.12 -0.24 62.33 -0.81 54.49 -1.55 45.38 -0.54 
76.55 -0.22 67.89 -1.58 108.37 -2.73 80.72 -1.59 75.00 -1.34 
100.12 -0.46 93.39 -1.89 154.41 -4.16 108.41 -2.73 106.21 -2.36 
146.51 -0.51 142.73 -2.02 208.89 -6.11 158.96 -3.98 151.88 -2.94 
304.14 -1.59 292.46 -4.27 373.32 -8.29 312.61 -6.78 269.51 -3.59 
 
5.3.3 Secondary hydrolysis reaction 
As in the previous sections, the effect of pH value and concentration on the rate of secondary 
hydrolysis was investigated. Figure 5.5 shows the consumption of ampicillin at multiple 
concentrations and a pH value of 7.00. As expected, the rate of reaction increases as the 
concentration of ampicillin increases. Following a similar procedure, the rate of reaction was 
estimated at multiple pH value and their values reported in Table 5.2. Although there is some 
scattering in the data, we can see that the rate of secondary hydrolysis increases as the pH value 
increases. However, the rates of hydrolysis at a pH value of 7.50 and 8.00 are not significantly 
different. At these pH values most of the ampicillin it is negatively charged (anionic state); 
hence, it is possible that these negatively charged molecules have better affinity with the enzyme 
binding site; thus, their rate of reaction is relatively faster than its neutral state. Considering that 
the pKa of ampicillin is at 7.31, we could expect a huge increment on the rate of reaction at any 






Figure 5.6: Hydrolysis of ampicillin at different initial concentration at a pH value of 7.00 and 
298K. 
 
Table 5.2: Initial rate of secondary hydrolysis v0 (mM min
-1) at multiple concentrations (mM) 
and pH values. 
[PGME]  v0 [PGME] v0 [PGME] v0 [PGME] v0 [PGME] v0 
pH 6.0 pH 6.5 pH 7.0 pH 7.5 pH 8.0 
3.77 -0.08 3.14 -0.41 2.75 -0.26 2.5 -0.25 3.08 -0.18 
7.23 -0.12 7.02 -0.18 5.63 -0.5 5.63 -0.5 6.26 -0.05 
9.86 -0.16 10.83 -0.25 8.2 -0.69 5.08 -0.44 9.21 -0.15 
13.09 -0.22 14.61 -0.41 11.08 -0.7 10.3 -1.02 12.52 -1.22 
- - - - -  20.75 -1.77 21.79 -0.61 
- - - - -   27.99 -2.11 31.07 -2.15 
 
5.4 Conclusions 
In this work the effect and concentration on the synthesis of ampicillin by PGA was 
investigated.  The reaction scheme was decouple into three different reactions: (1) synthesis vs. 
hydrolysis, (2) primary hydrolysis, and (3) secondary hydrolysis. The results demonstrated that 
the rate of each reaction increased as the pH value was raised. However, we did not see a 

































exhibited similar pH value dependence.  Therefore, we can conclude that the main variable to 
control in the process it is the ratio of the reactants. If 6-APA it is maintained in excess, synthesis 
of ampicillin will be favored over hydrolysis of D-phenylglycine methyl ester. However, such an 
approach will limit the conversion of 6-APA towards ampicillin.  In order to deal with this issue 
reaction configurations should be transformed from batch to semi-batch. This reactor design will 








Crystallization kinetics of ampicillin using online monitoring tools and robust 
parameter estimation routine 
6.1 Introduction 
As previously discussed, an alternative route for the manufacture of β-lactam antibiotics is 
the enzymatic synthesis by pencillin G acylase. This enzyme can catalyze the reaction of 
phenylglycine methyl ester (D-PGME) and 6-aminopenicillanic acid (6-APA) to form ampicillin. 
However, as shown in Figure 6.1, it also catalyzes the hydrolysis of D-PGME (primary 
hydrolysis) into phenylglycine (D-PG) and the hydrolysis of ampicillin into 6-APA and D-PG 
(secondary hydrolysis). 
 
Figure 6.1: Enzymatic synthesis of ampicillin by penicillin G acylase.  
As shown in Figure 6.1, the reaction network is a classic example of kinetically-
controlled synthesis where ampicillin must be removed from the system before it is consumed by 
secondary hydrolysis. Developing a means to accomplish this is the focus of the present work, 
which is aimed at developing a robust model for separation of ampicillin from the reaction 
medium by crystallization. Because such an operation would have to be integrated with the 
required enzyme-catalyzed reaction, the model must be applicable to a variety of crystallization 
conditions.  Previous work (Ottens et al., 2001, 2004) reported crystallization kinetics of 





ampicillin. The objective of our work is expanding the range of conditions for which the model 
and associated parameters are applicable. This requires investigating multiple crystallization 
variables such as both pH value and rate of change of pH value, initial supersaturation, and of the 
use of seed crystals. All were explored in a pH range that is suitable for an enzymatic reactive 
system (i.e., the crystallization kinetics were obtained over a pH range of 6.00 to7.50). 
Additionally, most of the work was done using online monitoring tools, which has become 
common in model development and control of crystallization processes (Fujiwara et al., 2005; 
Nagy et al., 2013). Typically, online process analytical technologies provide larger data sets that 
can be used in the design of more robust models. 
To accomplish these objectives the following strategy was developed. First, as described 
in Section 3.2, the necessary equilibrium data have been obtained from the literature and fit with 
a thermodynamic model that allows estimation of the solubility as a function of pH value. 
Second, in Section 3.3 results of induction time experiments are used to relate initial 
supersaturation with primary nucleation. This information was used to estimate the exponential 
primary nucleation constant. Third, in Section 3.4 a combination of seeded and unseeded 
crystallization experiments were used to obtain further information about both primary and 
secondary nucleation kinetics, and crystal growth kinetics. Finally, these sets of experiments 
were combined and a single set of parameters was obtained in Section 3.5. In Section 6.3.6, the 
parameters were used in the model to estimate the final crystal mean size of each run and 
compare it to the experimental one. 






 Anhydrous ampicillin was purchased from Alfa Alsear (Ward Hill, MA) and used 
without further purification. Ammonia was purchased in a 30% solution from Ricca Chemical 
Co. (Arlington, TX) and 5M hydrochloric acid was purchased from Sigma Aldrich (St. Louis, 
MO). 
6.2.2 Equipment 
Experiments to determine crystallization kinetics were performed in a 1 L OptiMax 
Synthesis Station from Mettler Toledo (Columbus, OH). A dosing unit was used to add 2 M HCl 
(diluted HCl 5M solution solution) to the reactor, and a pH probe unit from Mettler Toledo was 
used to monitor the pH in solution with a precision of ±0.001 pH units. Solution concentration 
was monitored using a MCP 500 polarimeter and an Abbemat 500 refractometer from Anton 
Paar by using signal-concentration calibrations shown in Appendix A.1.2. As shown in Figure 
6.2, solution was withdrawn from the reactor using a peristaltic pump and circulated through the 
refractometer and polarimeter.  Chord length distribution of crystals was monitored using a 
Focus Beam Reflective Measurement (FBRM) apparatus from Mettler Toledo. Further details on 
this unit can be found elsewhere (Shi et al., 2003). 
 





6.2.3 Crystallization Experiments 
The initial solutions in all crystallization experiments were obtained by charging the 1-L 
vessel with 500 g of DI-water and adding 2M NH3 solution until the pH was approximately 
7.75(exact pH were used to estimate the solubility). Then, the desired amount of ampicillin was 
added to the vessel and stirred at 300 RPM until all the particles were dissolved. The FBRM was 
used to monitor the appearance of new crystals and the evolution of the chord length distribution 
throughout the length of the run. In order to compare experiments, counts were normalized by 
the total counts in each run to take into account variations in the signal from run to run.  
Induction-time experiments were begun by abruptly changing the pH in the system in the 
range 7.85 to 6.00 by adding by adding 1 M HCl solution (exact pH were used to estimate the 
solubility). The time at which the FBRM had a rapid increase in chord counts was defined as the 
induction time.  
Unseeded crystallization runs were initiated by gradually changing the pH in the system 
in the range 7.85 to 6.00 by adding 1M HCL at a predetermined rate (specific conditions reported 
later). The solute concentration was measured by recirculating a small portion of the solution 
through the polarimeter and refractometer as described in Section 6.2.2, and the evolution of the 
chord length distribution was monitored using the FBRM. At the end of each run (after 
stabilization of polarimetric signal), crystals were filtered, dried, and examined by light 
microscopy. The aspect ratio of crystals was approximated by measuring the width and length of 
multiple crystals using the scales of pictures taken with a light microscope. 
Seeded crystallization runs were initiated by adding 1M HCl to reduce the pH in the 
system in the range 7.85 to 6.00 by adding (exact pH were used to estimate the solubility).  





gradually changed to 6 at a rate of predetermined rate using the acid dosing unit (specific 
conditions reported later). The solution concentration, evolution of the chord length distribution, 
and the recovery and analysis of crystals were accomplished as described in the preceding 
paragraph.  
 
6.3 Results and Discussion 
6.3.1 Crystallization kinetics 
Crystallization kinetics can be used to describe the evolution of crystal size distribution in 
a crystallizer. Equations 6.1 through 6.3 show a population balance along with initial and 
boundary conditions for a batch system in which agglomeration and breakage are neglected.  
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Alternatively, crystallization kinetics can be described by using the method of moments where 
instead of using a partial differential equation, an ordinary differential equation is employed to 
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Differentiation of the moments leads to expressions that contain nucleation and growth kinetics: 
                                                         0d J
dt

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In this work the following constitutive equations are used to model the rates of primary and 
secondary nucleation and crystal growth rate where [Amp] is the concentration of ampicillin, 
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Additionally, the rate of change of the moments of the distribution is related to the change in 
solution concentration through a mass balance.  This equation will be used in Section 6.3.5 to 
model ampicillin concentration and compare it with the experimental one. 







                                                 (6.11) 
6.3.2 Solubility 
All the crystallization protocols in this work are based on pH-induced supersaturation.  
Ampicillin is an ionizable compound that can exist in solution in three different forms (anion, 
cation, zwitterion ), where the ratio of these form will depend on the pH in solution. The 
distribution among the charged species can be related with the concentration at the isoelectric 
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where pKA =− log KA. 
Assuming that the solubility of the zwitterion [Amp±] is constant throughout the pH range 
of interest, the solubility of ampicillin ([Amp] = [Amp±]+[Amp-]) can be estimated using the 
Henderson-Hasselbach equation. Non-idealities in solutions can be included by using the 
extended Pitzer model (Pessoa et al., 2008) for electrolyte systems. This approach was used by 
Franco et al. (Franco et al., 2013) where they model the solubility of multiple ionizable 
compounds as a function of pH and temperature. However, in the present case we will focus on 
the pH dependence as the primary contributor to the solubility of ampicillin. Using this approach 
Equation 6.15 was used to fit solubility data, where parameters Aij and Bij  were used as 
adjustable parameters within the model. These parameters take into account non-idealities in 
solution, and are representative of the interactions in solution. Note that regardless the 




































































                                                           (6.18) 
 The solubility of ampicillin as a function of pH was obtained from the literature (Rudolph 
et al., 2001; Santana et al., 2010). Although there are differences between the two sources, our 
crystallization experiments tend to equilibrate at near-average values of their data.  
Figure 6.3 shows experimental and modeled values for the solubility of ampicillin as a 
function of pH, while Table 6.1 shows the parameters obtained by fitting experimental data.  
During the parameter fitting either the adjustable Pitzer parameters Aij and Bij or the 
thermodynamic parameters σ and ε/kB  can be used to fit the data as they are related by Equations 
6.17 and 6.18. As seen from the figure, when the pH is close to the isolectric point there is little 
difference between ideal and non-ideal solution behavior. As the pH increases, however, the 
solubility of associated with non-ideal solution behavior becomes greater than ideal behavior. 
This deviation from ideality is controlled by ε/kB, where a value greater than the experimental 
temperature makes the interaction parameters negative. Therefore, the solubility exhibits a 
negative deviation from ideality and its activity coefficient will be less than unity (i.e. solubility 
greater than the one of an ideal solution). This is expected as charged species should exhibit 



































Figure 6.3: Modeled and experimental solubility of ampicillin at different pH. 
 
Table 6.1: Extended Pitzer model parameters for ampicillin at 298 K. 
Aij Bij σ ε/kB λij 
11.05 -3.71x103 5.42x10-10 336.18 -1.42 
 
6.3.3 Nucleation Rate and Induction Time 
Primary nucleation rate can be related to induction time, which is the time between a 
solution becoming supersaturated and detection of  crystals (Sohnel et al., 1988).  Hence, 
induction time can be considered as the combination of the time required to create a nucleus and 
growing it to a detectable size:  
ind N Gt t t                                                                  (6.19)  
Assuming that nucleation is the limiting step (i.e. tN>>tG ), the induction period can be related to 
the rate of nucleation J as 
1
indt J






1J B                                                                   (6.21) 
and B1 is the rate of primary nucleation. Finally, by substituting Equation 6.7 into 6.20 and 



























                                                       (6.23) 
Figure 6.4 shows the total counts in the range of 0-10 μm for an induction time 
experiment at conditions reported in the figure. In this experiment, as mentioned in Section 6.2.3, 
instantaneous supersaturation was induced by addition of hydrochloric acid into the crystallizer 
and particles in solution were monitored using an FBRM.  It can be observed in the figure that 
the number or particles in the range of 0-10 μm spikes after 8 minutes. Hence, 8 minutes is the 



























Figure 6.4: Detection of induction time from FBRM data for induction time experiment 
of an initial supersaturation of 3.02 (C0/C0*) at 298 K. 
 
Following the procedure just described, induction periods at multiple initial 
supersaturations were obtained and fitted using Equation 6.23, as shown in Figure 6.5.  The slope 
of the regression represents the exponential primary nucleation constant  B0, which in this case 
was 1.27. Finally, using this value, Figure 6.6 was constructed.  These results show that an initial 
supersaturation of at least 1.75 is necessary to achieve nucleation within a practical time range. 



















































6.3.4 Crystallization experiments 
In the previous section induction time experiments were used to estimate the exponential 
primary nucleation constant B0. However, as can be seen in Equations 6.7 through 6.10 there are 
still 6 parameters to be determined in order to have a full description of the batch crystallization 
process.  In order to determine these parameters, a set of experiments consisting of seeded and 
unseeded crystallization runs were performed. In these experiments, multiple conditions such as 
initial concentration, rate of change of pH, initial mass of seed crystals (wt. %=mass of seed 
crystals/expected mass of product crystals), and initial supersaturation were changed from run to 
run accordingly to Table 6.2. The idea of this is to train the model with multiple conditions such 
that it can be used to predict system behavior under multiple crystallization protocols. 
Table 6.2: Crystallization runs experimental conditions 
Run Seed (wt. %)  
(wt.%) 
C0 S0 pH/h pH0 pHF 
a 0 15.94 0.98 1.0 7.47 5.97 
b 0 17.93 0.47 3.1 7.85 6.41 
c 0 18.09 0.54 6.0 7.84 
84 
6.45 
d 1.8 11.30 1.07 1.5 7.09 6.25 
e 3.0 11.36 1.18 1.4 7.01 6.34 
f 15.0 14.00 1.64 0.6 7.06 6.51 
 
Figure 6.7 shows concentration profiles of unseeded ampicillin crystallization 
experiments at three different rates of pH change and initial concentrations. The data were 
obtained by transforming signals from the polarimeter to concentration as described in Section 
6.2.2. As seen in the figures, more rapid changes in pH led to steeper desupersaturation curves, 
which is characteristic of a system undergoing extensive nucleation followed by rapid growth of 





since nucleation often occurred in the sampling loop. Nevertheless, the signal was stabilized 



















































































Figure 6.7: Unseeded crystallization for a rate of change of pH (a) 1.00 pH units/ h, (b) 3.10 pH 
units/h, and (c) 6.00 pH units/h. 
 
The effect of the rate of change of pH on crystal size distribution was determined by 
measuring the chord length distribution (CLD) of these runs. Figure 6.8, shows the final CLD for 
the runs in Figure 6.7. Note there is only a slight deviation between the final CLDs, and only 
Run c looks significantly different from the other two. It was expected that this run would have a 



































Chord Length ( µm )
 
Figure 6.8: Final chord length distribution of each run. 
 
 
As mentioned before, seeded and unseeded crystallization experiments were considered 
for the quantification of ampicillin crystallization kinetics. Hence, characterization of the seed 
crystals was necessary to define the initial conditions. Figure 6.9 shows crystal size distribution 
and chord length distribution of the seed crystals used in seeded crystallization experiments. The 
crystal size distribution was determined from sieve analysis, while chord length distributions 
were determined from FBRM data by adding seed crystals into a saturated solution and recording 
the resulting initial CLD.  Additionally, Figure 6.10 was used to determine the area and volume 
shape factors of the seed crystals used. This ratio along with crystal size distribution was used to 
determine the properties of the seed crystals shown in Table 6.3. The mean crystal size was 





is the sieve mid-size, and mTotal is the total mass.  The average crystal density was obtained from 
the literature (Ottens et al., 2001).  
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i=1











































































Table 6.3: Properties of ampicillin seed crystals. 
L seed (µm)  c  ( kg/m
3) 𝐤𝐚 𝐤𝐯 
104 1500 0.09 0.03 
 
Figure 6.11 shows concentration profiles for seeded crystallization experiments of 
ampicillin using different masses of seed crystals, initial concentrations, and rates of change of 
pH. The same plots show the solubility curves for each case, where the solubility of ampicillin 
was maintained below the concentration at any given time. Initial supersaturations were design 
such that the system supersaturation was within its metastable limit. The data in Figure 10(f) 
show that significant amounts of seed crystals were necessary to induce fast desupersaturations. 
This is in agreement with the crystallization parameters that will be presented later since the 
exponent of mass of crystals is relatively small.  It is expected that this behavior would not only 
depend on the mass of seed crystals, but on their size distribution. Hence, keeping the total mass 
constant and using seed crystals with a smaller mean size would reduce the necessary mass 
needed to promote secondary nucleation as the total surface area increases. Details on how to 
approximate such a critical mass for different sizes can be found elsewhere (Doki et al., 2002; 
Tseng et al., 2014). Additionally, final CLDs of runs d and f are shown in Figure 6.12 (Run e 























































































Figure 6.11:  Crystallization of ampicillin using seed loads (d) 1.8 % wt., (e) 3.0% wt. and (f) 
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6.3.5 Crystallization Kinetics Parameter estimation 
In the previous sections the data necessary to obtain crystallization kinetics was 
determined from seeded and unseeded crystallization experiments. In this section, Equations 6.4-
6.11 will be used to fit the experimental data where primary nucleation, secondary nucleation, 
and crystal growth rate parameters will be determined. The exponential factor B0 was the only 
parameter fixed prior to the parameter-estimation routines, as it was determined from the work 
described in Section 6.3.3. Equation 6.11 represents the rate of change of the concentration of 
ampicillin in solution, which was related to the moments using a mass balance. This mass-based 
moment was compared to the experimental concentration, and their difference was minimized in 
the parameter estimation routine. Initial conditions were based on initial concentration and the 
mass of seed crystals and their average length and aspect ratio. 
Estimation of parameters in the kinetic expressions was performed using the 
following objective function: 
exp
exp 2
( , ) ( )
1 1
min ([Amp] [Amp] )
N Nx




                                                   (6.25) 
where [Amp]i(t,p)  represents the modeled concentration at some set of parameters p = [kB1 kB2 b  s 
kg g], 
exp
( )[Amp]i t  represents the set of concentrations determined experimentally, Nx  is the 
number of data points, and Nexp the number of experiments ( Nexp = 6) .  Usually, estimation of 
crystallization kinetic parameters leads to multiple solutions (combinations of parameters) that 
provide good  equally good fits of the experimental data. Therefore, to minimize the probability 
of being trapped in a local minima two consecutive minimizations of Equation 6.25 were 
performed. First, a stochastic minimization (MATLAB simulannealbnd) was used to identify the 
best set of parameters among a wide range. This minimization is specially a good idea when 





minimization were used as the starting point of a deterministic minimization (MATLAB 
fminsearch) which refines the parameters and further reduce the error. The utilization of a large 
data set, where multiple operational conditions were included allowed us to obtain a single set of 
parameters that have predictability capabilities over a wide range of conditions. Even though the 
fitting of a single experiment is more accurate for that specific experiment, its parameters could 
not provide a good fitting when the conditions were changed. The results of the multi-
experimental approach are shown in Figure 6.13, and as it can be seen the model is capable of 
fitting all the conditions tested. 
In order to address the robustness of the parameters, confidence intervals were evaluated 
using a parameter perturbation method as reported by Nagy et al.(Nagy, 2008) and Rawlings et 
al. (Miller et al., 1994). Additional information on the effect of parameter uncertainty and how to 
minimize its effect was reported by Ma et al.(Ma et al., 1999) and Nagy et al. (Nagy et al., 2004). 
In this case, let Sp represent a measurements matrix that contains the sensitivities matrixes (
iy
pS ), 
P the precision matrix, and V the covariance matrix.  
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RV s P                                                                      (6.29) 
Using the previous equation confidence intervals can be calculated; in this case, a t-test 
evaluation for a 95% confidence was used to estimate the intervals. 
* ( )p p t diag V                                                            (6.30) 
Table 6.4 shows the results of the parameter estimation routing along the respective absolute 





experiments. As it can be seen in the table when a single experiment is used for the calculation of 
confidence intervals, the respective intervals are very broad. In some cases even bigger than the 
actual parameter, which would not have any physical meaning (i.e. negative nucleation rates).  In 
contrast, as the number of experiments is increased, the confidence interval gets so narrow that it 
appears that the calculated set is very close to the true set. It is obvious that this analysis does not 
provide any proof that the obtained set is a global minima. However, it certainly demonstrates 
that the multi-experimental parameter estimation routine provides superior estimates than these 
of single experiment routines.  In other words, the greater the number of experiments, the less of 
possible solutions that can reduce the error. In this case, 6 experiments were sufficient to 
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s kG (m/min)  
 
g 
θ 5.24x1010 1.27 6.63x108 0.3
4 
1.37 1.07x10-5 1.87 
 ± (Run d) 6.38x1010 - 2.24x1010 1.2
3 
77.66 4.51 x10-6 0.38 
± (Runs d-f) 2.43x1010 - 2.10 x108 0.0
3 
0.11 1.75 x10-6 0.08 
 ±(All runs) 2.77 x109 - 3.06 x107 0.0
1 
0.04 1.93x10-7 0.02 
 
6.3.7 Approximations on crystal mean siz 
The utility of the kinetic parameters was tested by assessing predictions of crystal size 
distribution. First, we recognize that the crystallization kinetic expressions were obtained from 
concentration data; therefore, the model should predict the desupersaturation behavior but not 
necessarily the corresponding crystal size distribution. To see if the model has any capabilities of 
predicting CSD, the final number-based chord length average was calculated. 
 
n
CLD i i Total
i=1
L = n L /n                                                   (6.31) 
  
It is expected that this mean size will be significantly lower than the mean size of the CSD. This 
is because it is very improbable that the laser will cross all the crystals through their 
characteristic length. Instead, just the fraction of crystal that is aligned with the laser beam will 
be identified as the length of the crystal. In order to factor this in, we compared the mean size of 
the CSD of the seed crystals with the mean size of their CLD. A ratio these means was calculated 
and called k (i.e. /CSD CLDk L L ). This constant was used to transform the mean of the CLD into 
a CSD mean as shown in Equation 6.32. Finally, to assess the validity of the model, the moments 






CSD CLDL kL                                                              (6.32) 
1, 0,Model end endL                                                          (6.33) 
 
The second column in Table 6.5 shows the mean size of the final CSD for each run 
obtained by using Equation 6.32, while the third and fourth columns show the mean size 
obtained from the moments of the distribution (Equation 6.33). The third column represents the 
estimated mean using the parameters obtained from a multi-experimental, while the fourth 
column represents the estimated mean when only Run f was used in the parameter estimation 
routine. Note that when the parameters obtained using all the experiments were used, the 
modeled mean size is relatively close to the experimental one. In contrast, when a single 
experiment is used, the mean size greatly deviates from the estimated experimental values. 
Therefore, we can conclude that by employing such a multi-experimental parameter estimation 
routine we can obtain a set of parameters from concentration data that provide relatively good 
estimates on the average size of crystals.  This observation can be quantified by determining the 
error between experimental and modeled means, obtaining an error of 6% for the multi-
experimental approach vs. 38% for the single-experiment approach. This methodology can be 
useful as in many cases transformation from CLD to CSD can be time consuming. This is 
especially true when crystals have very small aspect ratios as in the case of needles, where CLD 
data is best used as a qualitative indicator of the direction of the process (Leyssens et al., 2011). 
In a more robust approach  the characteristic chord length at each crystal size is obtained and the 









Table 6.5: Final mean crystals size obtained from modelling and fitting of CLDs. 
 
Run Experiment (µm) Model All (µm) Model Run f (µm) 
a 99 103 63 
b 103 102 56 
c 113 113 38 
d 115 123 51 
f 90 112 87 
   
6.4 Conclusions 
  In this work crystallization kinetics of ampicillin were determined from a large set 
of data obtained from an online monitoring system. This system allows us to follow the system 
concentration and chord length distribution. The data from all the experiments were combined 
and, using stochastic and deterministic minimizations, crystallization kinetics were determined. 
Since the data span multiple rates of pH change, supersaturations, and amounts of seed crystals, 
the parameters should be more useful than parameters obtained at a fixed condition. This was 
demonstrated by doing a confidence interval analysis for different numbers of experiments, 
which showed that the confidence interval gets narrower as the number of experiments is 
increased. Such an analysis provides information about the minimum number of experiments 
required to obtain a robust set of parameters. Additionally, the utilization of a wide range of 
conditions allowed us to obtain parameters that not only predict concentration profiles, but also 






Reactive crystallization of β-lactam antibiotics: Strategies to enhance 




β-lactam antibiotics are among the top in the list of most used pharmaceutical compounds 
worldwide.  In fact, antibiotics span 5% of the global pharmaceutical market with sales greater 
than $42 billion in the United States(Hamad, 2010). These compounds have been of great utility 
during the past decades because of their effectiveness in treating bacterial infections. For this 
reason β-lactams are listed by the World Health Organization (WHO) as an essential medicine in 
any country. Conventional production of β-lactam antibiotics includes several chemical 
processes in which sub-zero temperatures, organochloride solvents, protection and deptrotection 
groups, and additional raw materials are required during the process (Ospina et al., 1996).   As 
many pharmaceutical processes, these processes have a high E-factor (35 kg of raw material/kg 
of product). 
An alternative route for the manufacture of β-lactam antibiotics is the enzymatic synthesis by 
penincillin G acylase (PGA). This enzyme can catalyze the acyl transfer from an activated side 
chain donor to the nucleophilic β-lactam forming the desired antibiotic. As for example, 
enzymatic synthesis of ampicillin can be achieved by reacting 6-aminopenicillanic (6-APA) acid 
with D-phenylglycine methyl ester (D-PGME) in the presence of PGA. Similarly, other β-lactam 





The overall reaction scheme is presented in Figure 7.1. As can be seen, PGA catalyzes the 
synthesis of ampicillin and, unfortunately,  it also catalyzes the hydrolysis of D-PGME to D-
phenylglycine and the hydrolysis of ampicillin to D-phenylglycine and 6-APA. In fact, 6-APA 
production can be achieved through hydrolysis of penicillin G by PGA (Abian et al., 2003).  
 
Figure 7.1: Enzymatic synthesis of ampicillin by PGA. 
The synthesis of ampicillin illustrated in Figure 7.1is kinetically controlled, meaning the  
ampicillin is an intermediate within the reaction network. Multiple reaction-engineering 
strategies have been used to improve the conversion of 6-APA to ampicillin. These strategies can 
be classified into thermodynamically controlled reactions or kinetically controlled reactions. The 
first relies on optimization of the reaction medium to shift the microscopic reversibility of the 
enzymatic reaction towards the synthesis reaction. Based on the fact that the undesired reaction 
is an hydrolysis reaction, organic co-solvents have been used to shift equilibrium towards 





demonstrated to improve the equilibrium constants but the kinetics of reaction can be drastically 
reduced.  
Reaction optimization is possible by acquiring information about the three main reactions: 
(1) synthesis, (2) primary hydrolysis, and (3) secondary hydrolysis.  Significant work has been 
done in this area, including building kinetic models, optimization of pH and temperature of the 
reaction, heterogeneous reactions, and complex reactor design (Ferreira, 2007; Youshko, Chilov, 
et al., 2002; Youshko & Svedas, 2000; Youshko, van Langen, et al., 2002).  Among these, 
reaction with product precipitation seems like a promising alternative due the advantage of 
obtaining high concentrations of product and recovering it in the solid phase.   Several authors 
have reported the possibility of precipitating ampicillin while is being produced in solution 
(Ferreira, 2007; Youshko, van Langen, et al., 2000).  However, as far as we know, ampicillin 
precipitation was accompanied by precipitation of D-phenylglycine. This has some potential 
downstream disadvantages, as it will be necessary to design a strategy for separation of the two 
crystallized species.  Unfortunately, as far as we known there is only a single publication that 
discusses the separation of ampicillin from D-phenylglycine (Hoeben et al., 2009). 
In the present work we have developed a reaction-crystallization protocol in which ampicillin 
is the only product crystallized. In order to achieve this goal, we have used information about 
solution thermodynamics, and reaction and crystallization kinetics.  The experimental results 
indicated that the best protocol to ensure high product recovery and purity is a reactive seeded 
crystallization. In the following sections we demonstrate the process by showing reaction data, 






7.2 Materials and Methods 
7.2.1 Chemicals 
D-Phenylglycine methyl ester (PGME) was purchased from Sigma Aldrich USA (St. 
Louis, MO), 6-aminopenicillaninc acid (6-APA), phenylglycine (PG) and ampicillin (Amp) 
were purchased from VWR USA (Radnor, PA). Penicillin G acylase from E. Coli was kindly 
donated by DSM-Sinochem (The Netherlands). The enzymatic solution had a concentration 
of 17 mg/mL of protein its purity was verified using a SDS-PAGE gel showing no indication 
of other proteins.  All the chemicals and enzyme were used without further purification.  
7.2.2 Enzymatic Reaction 
The enzymatic synthesis of ampicillin was performed in 10-mL test tubes with a working 
volume of 5 mL. The temperature was maintained at 25 °C using a water-bath shaker operated at 
150 rpm. The reactants were added to the 10-mL test tubes and dissolved using deionized water 
and adjusted to the desired pH using 5N ammonia. Reactions were started by addition of 50 µL of 
the enzymatic solution. Samples were withdrawn as a function of time to construct concentration 
profiles by removing 50 µL aliquots from solution. If product precipitation was evident 
approximately 0.5 mL of the slurry were filtered and the clean solution was used to obtain the used 
to obtain the 50 µL aliquots.  
7.2.3 Scale-up and particle tracking 
Reaction crystallization experiments were scaled up from 5 mL to 250 mL using the 1-L 
OptiMax Synthesis Station from Mettler Toledo (Columbus, OH) shown in Figure 7.2.  Reaction 
mixtures were prepared by dissolving the desired amount of 6-APA and D-PGME and adjusting 
the pH using 5N ammonia. Solution temperature was maintained at 25 °C and a stirrer speed of 





solution was withdrawn with a syringe and a 0.45-µm filter was used to remove particles from 
the solution. Chord length distribution of crystals was monitored using a Focus Beam 
Reflectance Measurement (FBRM) apparatus from Mettler Toledo. Further details on this probe 
can be found elsewhere (Shi et al., 2003). 
 
Figure 7.2: 250 mL reactive crystallization set up. 
7.2.4Analytical Methods 
Solution concentration was analyzed using a Shimazdu (Kyoto, Japan) high-pressure 
liquid chromatography (HPLC) system. Aliquots of 50 µL where withdrawn using a micropipette 
and diluted in 1mL of HPLC solution with 1  vol%2M HCl to quench the reaction.  If particles 
were present in solution, approximately 0.5 mL of slurry was withdrawn with a syringe and 
filtered prior taking the 50 µL aliquot. HPLC solution consisted of an aqueous solution of 
0.68g/L KH2PO4, 0.68g/L SDS at a pH of 3.0 and acetonitrile (70  vol% aqueous/30  vol% 
organic). A C18 Kinetix column from Phenomenex (Torrance, CA) was used.  
Calibration curves were obtained at a pH of 6.00 and 7.00 to ensure that the absorbance 





pH of solution was changed as charged species had a different retention time than zwitterions. 
However, charged and neutral species exhibit the same UV absorbance as a function of 
concentration. 
7.3 Results and Discussion 
 
7.3.1 Solubility  
Since the goal of this work is to design a reactive crystallization scheme that facilitates 
recovery of high-purity ampicillin, it is necessary to obtain information about the solubility of all 
components in the system. Figure 7.3 shows the solubilities of ampicillin, D-phenylglycine, and 
6-APA as a function of pH (Santana et al., 2010). Data on D-PGME was not considered as its 
solubility is significantly higher than that of other components in the system. As shown in the 
figure the solubilities of ampicillin and D-phenylglycine are significantly lower than that of 6-
APA. These results indicate the feasibility of designing a reactive crystallization scheme since 
the concentration of ampicillin reaches its solubility with only partial conversion of 6-APA. 
Additionally, we see that the solubility of ampicillin and 6-APA exhibit a strong dependence on 
pH in contrast to D-phenylglycine. This behavior can be attributed to the difference in the pKa of 
each molecule (Franco et al., 2013; Pessoa et al., 2008). Ampicillin and 6-APA have smaller pKa 
values, meaning that their fractions of negatively charged species will be higher, and, typically, 




















































Figure 7.3: Solubility of ampicillin, D-phenylglycine, and 6-APA (right axis) as a function of pH 
at 298 K. Data from Santana et al. 2010. 
7.3.2 Reaction at highly concentrated conditions 
 In the previous section the solubility of ampicillin, D-phenylglycine, and 6-APA was 
presented. According to these data, the solubility of ampicillin should be easily reached during 
its synthesis when using relatively high concentrations of substrate. Hence, we tested reactions at 
conditions in which ampicillin crystallization should be possible ([6-APA]0= 200mM); at these 
conditions, only ~15% conversion is necessary to reach the solubility of ampicillin. Figure 7.4 
shows the concentration of ampicillin as a function of time at multiple initial concentrations of 
D-PGME. The data show that the rate of synthesis was enhanced when the concentration of D-
PGME was increased. However, Figure 7.5 shows that such conditions also enhanced the rate of 
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Figure 7.4: Synthesis of ampicillin at 25oC and pH of 7. Initial concentration of 0.20 M 6-APA 
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Figure 7.5: Accumulation of D-phenylglycine at 25oC and pH of 7. Initial concentration of 0.2 M 
6-APA and D-PGME 100-300. 
Yousho et al. (2002) developed a model that predicts reaction kinetics for this complex 
reaction (Youshko, Chilov, et al., 2002). The results of this model are show in Equation 7.1, 
which indicates that an increase in D-PGME concentration will decrease the selectivity of the 
reaction because a significant amount of substrate is lost through primary hydrolysis. 
[Amp]
[ ]
[ ][ ] [Amp](1 [ ])
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 As observed in Figure 7.4, the concentration of ampicillin did not decrease at any point 
throughout the runs. This indicates that no crystallization occurred during the process even 
though very high supersaturations were reached, even though the maximum supersaturation (S = 





 Since no product crystallization was occurred in any of the previous examples, the initial 
concentration of 6-APA was raised to 0.50 M and D-PGME to 0.75 M. Concentration profiles of 
ampicillin and D-phenylglycine for such reaction are shown in Figures 7.6 and 7.7, which show 
the concentration of ampicillin reached 0.30 M before showing a slight decrease in its 
concentration.  On the other hand, D-phenylglycine concentration started to decrease after 100 
mM.  Crystals were observed in the system after 100 minutes, meaning that D-phenylglycine 
precipitation was taking place. Analysis of the solid phase indicated a purity of only 4.85 wt% 
ampicillin. Hence, we attribute a significant portion of the decay in ampicillin concentration to 
secondary hydrolysis because high concentrations of ampicillin favor that reaction. In the next 























































Time (mM)  
 
Figure 7.7: D-phenylglycine concentration profile of reaction starting with 0.50 M 6-APA and 
0.75M D-PGM. 
 
7.3.3 Ampicillin nucleation and crystallization 
When a homogeneous supersaturated solution reaches sufficiently high supersaturation, a 
new crystalline solid phase forms and the mechanism of its formation is referred to as primary 
nucleation. As described in Chapter 6, it is possible to relate primary nucleation kinetics to 
induction time, which is the time that elapses between a solution becoming supersaturated and 
when crystals of a detectable size are observed in solution (Sohnel et al., 1988). To reach such a 
detectable size, a nucleus of an indistinguishable size must be created and grown to the micron 
range. Therefore, the total time of this process can be divided into the time required to create a 
nucleus and the time required to grow it to a detectable size. 





In most cases it is acceptable to assume that nucleation is the limiting step (i.e. tN >> tG ); hence, 
induction periods can be related to the rate of primary nucleation.  
1
1indt B
                                                                   (7.3) 








                                                   (7.4) 
Substitution of Equation 7.4 into 7.3 leads to an expression that can be used to relate induction 
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                                                        (7.5) 
Linearization of Equation 7.5 yields an expression whose slope represents the exponential 
primary nucleation constant. This constant controls the onset of primary nucleation and can be 
used to obtain relationships between supersaturation and induction periods. More details on 
induction periods and  the physical meaning embodied in the constants can be found elsewhere 











                                                       (7.6) 
Ottens et al. (2001) reported on induction-time experiments that were performed to 
estimate the primary nucleation rate constant B0 (Ottens et al., 2001). In a later work by the same 
group Ottens et al. (2004), the effect of multiple impurities on ampicillin crystallization was 
reported. According to their results, reaction substrates and by-products inhibit ampicillin 
crystallization. This behavior is illustrated for three different initial concentrations of 6-APA in 
Figure 7.8, which shows induction periods as a function of initial supersaturation based on the 





























Figure 7.8: Log of induction time against log of inverse of initial squared. Data obtained from 
Ottens et al., 2004. 
The slope of each plots represents the primary nucleation constant B0 for the given 6-APA 
concentration. As shown in Figure 7.9, the slopes follow a linear relationship over the 
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Figure 7.9: Nucleation rate constant Bo as a function of 6-APA concentration. Data obtained from 
Ottens et al., 2004. 
 
Finally, just for qualitative purposes we have performed an extrapolation of the 
nucleation rate constant to higher concentrations of 6-APA (up to 150 mM) by using the slope 
calculated in Figure 7.9.  Using these nucleation rate constants, we predicted the required 
induction time as a function of the concentration of 6-APA at multiple initial supersaturations.  
As seen in Figure 7.10, 6-APA concentration strongly affects induction periods, which may 
explain why ampicillin crystallization was not possible at a supersaturation as high as 5. In fact, 
at such conditions a supersaturation of approximately 10 is predicted to be necessary for primary 


































Figure 7.10: Extrapolation of induction time against 6-APA concentration at multiple 
supersaturation levels. 
 
 Usually, extremely high supersaturations are undesirable in crystallization processes. 
These typically induce uncontrolled nucleation leading to small crystals and incorporation of 
impurities.  Additionally, as mentioned in the previous section, increasing the concentration of 
the substrates led to D-phenylglycine precipitation (<5% wt. ampicillin).  Hence, in order to 
reduce the required initial supersaturation for crystallization and improve solid-phase purity, 
addition of seed crystals are explored in the next section. 
7.3.4 Seeded reactive crystallization 
 As discussed in the previous section, unseeded experiments did not lead to crystallization 
unless the concentration of substrates was raised to very high concentrations.  In this section 
seeded crystallization is explored since secondary nucleation can promote crystal formation at 





results of seeded reactive crystallizations at conditions described in the figures. In these 
experiments the solution was seeded with 0.05 g of ampicillin crystals after 2 hours of starting 
the reaction.  The time for seeding the solution was seeded was based on the concentration 
profiles of unseeded reactions. As seen in Figure 7.4, after 2 hours the concentration of 
ampicillin was higher than its solubility at the conditions of the reaction. Hence, solutions were 
seeded after two hours and it can be observed that the concentration starts to decrease after 4 
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Figure 7.11: Accumulation of ampicillin at 25oC and pH of 7.00. Initial concentration of 0.20 M 






Figure 7.12 shows that the D-phenylglycine concentration profiles for the same 
experiments continuously increased, which is evidence that crystallization of D-phenylglycine 
did not occur during the process.  The data demonstrate one of the potential advantages of seeded 
reactive crystallization:  i.e. the desired product is selectively recovered in the solid phase as it is 
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Figure 7.12: Accumulation of D-phenylglycine at 25oC and pH of 7.00. Initial concentration of 
0.20 M 6-APA and D-PGME 0.20 M to 0.30 M and seed load of 0.05g.  
The effect of the specific time at which the seed crystals were added was determined by 
maintaining the amount of seed crystals constant and varying the time at which they were added 
to the system. Figures 7.13 and 7.14 show the concentration profiles of ampicillin and D-
phenylglycine when the seed crystals were added at 30 min, 60 min, and 120 min. As seen from 
Figure 7.13, adding seed crystals at 30 min maintained lower ampicillin concentration as 





seeding at different times on the concentration profiles of D-phenylglycine; again, there was an 
insignificant effect on the concentration of D-phenylglycine, providing further evidence that the 
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Figure 7.14: Effect of seed time on D-phenylglycine concentration profiles. 
To investigate the effect of the mass of seed crystals on product concentration profiles, 
three different seed-crystal loads were added to the reaction system after 2 hours. Figure 7.15 
shows the concentration profiles of ampicillin using seed-crystal loads of 0.01g, 0. 05 g, and 
0.10g.  As expected, higher loads enhanced crystallization rates and maintained lower 

































Figure 7.15: Accumulation of ampicillin at 25oC and pH value of 7.00. Initial concentration of 
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Figure 7.16: Accumulation of D-phenylglycine at 25oC and pH value of 7.00. Initial 





 In order to determine the purity of the recovered crystals, solutions were filtered 
after 6 hours, dried at room temperature, and the solid phase was analyzed through HPLC. The 
results in Table 1 show that high purity resulted in all the runs in which seed crystals were used. 
In fact, the mole fractions of D-phenylglycine in the solid phase were similar to those of 6-APA 
and D-PGME, which implies that the impurities in the solid phase resulted from entrapment or 
adherence of the filtered solution. It is worth noting that the recovered crystals were not washed, 
as they would be in an industrial setting. Moreover, ampicillin crystallizes with a needle-like 
morphology, which limits the efficiency of washing and filtration. 










Purity (wt. %) 
1 0.20 0.30 0.00 - - 
2 0.20 0.30 50.0 30 98.36 
3 0.20 0.30 50.0 60 99.08 
4 0.20 0.30 10.0 120 99.36 
5 0.20 0.30 50.0 120 95.17 
6 0.20 0.30 100.0 120 92.26 
7 0.20 0.20 50.0 120 99.75 
8 0.50 0.75 0.00 - 4.85 
 
The previous experiments were performed with a total volume of 5 mL. Additionally, 
during the experiments aliquots of approximately 0.5 mL were withdrawn every time a sample 
was prepared, meaning roughly 60% of the material was lost through sampling. This does not 
consider all the material lost during transferring and filtration; thus, the total material recovered 
is certainly less than the one produced by the process. Hence, the total amount of crystals 
produced was approximated from the following equation.  
 






First, it is assumed that in the absence of crystallization the concentration should follow a trend 
similar to that of run 1 in Table1. This run was used as a baseline for reactive crystallization 
experiments at the same initial conditions (i.e. initial concentration of substrates). Then, we 
attribute the difference in concentration between those to crystallization. Finally, using Equation 
7.7 we have estimated the accumulated mass of crystals after 6 hours for different crystallization 
protocols. 
Table 7.2: Comparison of mass of crystals produced after 6 hours for selected runs (Calculated 







1 0.20 0.30 0.0 
2 0.20 0.30 84.7 
3 0.20 0.30 75.3 
4 0.20 0.30 34.3 
5 0.20 0.30 67.7 
6 0.20 0.30 72.73 
 
For qualitative purposes, pictures of the reactive crystallization through the length of the 
reaction are shown in Figure 7.17. There is a clear progression from a clear solution to a cloudy 







Figure 7.17: Picture of reactive-crystallization Run 4 and 5 when reaction started (left), after 
seeding (center), and after 6 hours (right). 
 
7.3.5 Scale-up and CLD evolution 
 In order to have better understanding of the process, the reaction was scaled up from 5 
mL to 250 mL. At this scale an FBRM probe can be used to monitor particles the chord length 
distribution in the slurry. Additionally, the final mass of crystals can be measured as losses 
during the experiment are insignificant in comparison with the mass of crystals recovered. Figure 
7.18 shows the concentration profile for such a run in which 2.5 g of ampicillin seed crystals 
were added after 1 hour of reaction time. The concentration profile looks very similar to those 
obtained using the 5-mL vessels in which a decay in concentration was observed when the 
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Figure 7.18: Reactive crystallization scale-up to 250 mL(6-APA 0.20 M, D-PGME 0.30 M, 25 
oC, and pH 7.00). 
 Figures 7.19 and 7.20 show FBRM data for the same run. In Figure 7.19 the increase in 
chord counts at around 200 minutes is thought to result from secondary nucleation, which is 
consistent with the concentration profiles shown before as the concentration of ampicillin starts 
to decay at that point. Additionally we note that 30 to 60 minutes after nucleation, the number of 
small particles (0 to 50 µm) starts to decay while the number of big particles (50-300 µm) keeps 
increasing. Hence, after that point supersaturation is being depleted by crystal growth rate rather 
than nucleation. This is reflected by the evolution of chord length distribution (Figure 7.20) 
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Finally, the mass of recovered crystals was quantified after filtration and drying of the 
cake. In this case a total mass of 8.5 g was recovered from the process. This mass includes 
2.5 g of seed crystals, thus 6.0 g of solid ampicillin were produced in the process. 
Additionally, solid-phase purity was determined by HPLC to be 99.05 wt% ampicillin. 
Ampicillin crystals yield should be slightly higher as some ampicillin was lost through the 
process as a result of samples withdrawing, filtration, drying, and a portion that remained 
stick to the vessel, baffles, and probes. 
7.4 Conclusions 
In this work we have demonstrated the advantage of performing a reactive seeded 
crystallization towards the manufacture of ampicillin. First, we demonstrated that unseeded 
reaction did not show product crystallization even after reaching high supersaturation (i.e. 
supersaturation of 5). In order to induce product precipitation without the presence of seed 
crystals, substrates initial concentrations were raised even more. However, this led mainly to 
crystallization of D-phenylglycine obtaining 5% wt. solid phase purity with respect to ampicillin. 
This problem was successfully resolved by the addition of seed crystals into the reaction vessel 
as crystallization of ampicillin was possible in all the runs. Solid phase purity analyses 
demonstrated that very high purities are possible with such an approach. Additionally, the effects 
of multiple seeding protocols were demonstrated in this work. Hence, in contrast to other 
heterogeneous reactive synthesis, seeding provides a selective separation in which crystallization 
of the desired product is promoted. As do other reactive crystallization processes, this operation 
has the advantage of reducing the rates of secondary hydrolysis because ampicillin is protected 
from the enzyme whenever it is in the solid phase. Additionally, the total manufacturing time is 





                                                                CHAPTER 8 
Future Work 
8.1 Reactive crystallization towards the manufacture of chiral compounds  
8.1.1 Extension to multiple substrates 
 In Chapter 3 the possibility of performing chemoenzymatic stereoinversions at conditions 
at which crystallization of enantiomerically pure crystals was possible was demonstrated. This 
process was demonstrated by resolving mixtures of DL-methionine and DL-phenylalanine, 
where in both cases enantiomeric purities over 99% wt. were obtained. In addition, D-amino acid 
oxidases can be used to oxidize a broad range of amino acids. Alexandre et al. discussed the 
efficacy of multiple reducing agents in the chemo-enzymatic stereoinversion of amino acids 
(Alexandre et al., 2002). In the same work, 10 other amino acids are converted to single 
enantiomers but their success was not the same for all the amino acids tested.  
 Another enzyme that has shown great oxidation enantioselectivity is sec-alcohol oxidase 
(Fantin et al., 1993; Muller et al., 1991). This enzyme shows great enantioselectivity towards the 
oxidation of sec-alcohols. Following a similar scheme to the one used for the conversion of 
chiral amino acids to a single enantiomer, stereoinversion of sec-alcohols it is possible. Kroutil et 
al. developed a mathematical framework that can be employed to predict the stereoinversion of 
sec-alcohols through cyclic chemo-enzymatic stereoinversion (Kroutil et al., 1998). Upon the 
availability of thermodynamic information about the solubility of these compounds in their 








8.1.1 Alternative of reactors design 
 The work presented in Chapter 3 was performed in a batch reactor. Batch reactors are the 
standard in the manufacture and purification of specialty chemicals and pharmaceutical products.  
In the work presented in Chapter 3, a reaction-crystallization scheme was developed using a 
single batch unit to decrease reactor volume and reduce operational time. The time of the 
operation was reduced as both reaction and separation could be performed in parallel. However, 
this has some potential disadvantages. For example, conditions that favor the reaction do not 
necessarily favored crystallization. As discussed before, relatively high temperatures enhance the 
rate of reaction. However, these temperatures increase the solubility of the substrates which 
reduced crystallization rates. 
 It is possible to transform this operation into a continuous operation where one section of 
the process used for reaction while the other is used for separation.  Using this approach is 
possible to run both reaction and crystallization at their optimal point. As shown in Figure 8.1, 
the reaction can be run using two stages where in the first stage the reaction is run until the 
desired enantiomeric excess is achieved while in the second stage crystallization of the 
enantiopure product will take place.   
     






8.2 Reactive crystallization towards the manufacture of β-lactam antibiotics 
8.2.1 Extension to multiple substrates 
 In Chapter 7 a strategy towards the synthesis and recovery of ampicillin in a single stage 
was demonstrated. This was achieved by performing a seeded reactive crystallization in which 
ampicillin was produced and recovered with high purity in the solid phase. However, this process 
was only demonstrated for ampicillin as a target product. Nevertheless, penicillin G acylase has 
shown activity towards a wide range of β-lactam that can be utilized to produce other antibiotics 
such as amoxicillin, cephalexin, cefadroxil, and others (Wegman et al., 2001).  Hence, a reactive 
crystallization towards the manufacture of these antibiotics is viable. In fact, if amoxicillin is the 
target product, co-product precipitation can be alleviated as the solubility of D-(hydroxyl)-
phenylglycine is higher than the one of D-phenylglycine (Rudolph et al., 2001). 
  
8.2.2 Reaction optimization 
 In Chapter 5 an experimental design consisting of 6 concentration levels at 5 pH values 
was performed. Our results demonstrated that pH has a significant effect on the rates of 
reactions, but not necessarily on the selectivity. However, in the case of reactive-crystallizations 
the pH value will not only affect the rates of reaction, but it will also affect solid-liquid equilibria 
and crystallization kinetics. In Chapter 4 a generic model for optimization of temperature-
dependent reactive crystallizations was developed. In that case, at high temperatures the rates of 
reaction were favored, while at low temperatures the rate of crystallization was enhanced.  The 
objective of such optimization was to maximize the productivity of the operation by finding the 





optimization embodied both reaction and crystallization kinetics, and their respective 
dependence on temperature. Using these relations, an optimal temperature path was developed.  
 As mentioned before, in Chapter 5 reaction kinetics were addressed through a variety of 
experiments. Additionally, in Chapter 6 crystallization kinetics of ampicillin were developed. 
Using reaction and crystallization kinetics a dynamic optimization like the one presented in 
Chapter 4 is possible. In this case, pH can be used to control substrate concentrations, which in 
turn control the rates of reaction. On the other hand, supersaturation can be controlled by 
manipulating the pH value in solution. Therefore, an optimal pH path can be developed such that 
process or product attributes are enhanced.  
 
8.2.2 Effect of impurities on ampicillin crystallization 
 Ottens et al. developed models to predict crystallization kinetics of ampicillin with or 
without impurities (Ottens et al., 2001, 2004).  In their work, the effect of substrates and by-
products concentration on the crystallization of ampicillin were quantified. However, the only 
way in which concentrations of ampicillin can be obtained is if high concentrations of substrates 
are used. Unfortunately, the results in Ottens et al. do not represent the conditions at which the 
reaction is performed nor the concentration of substrate that are commonly used.  
 In the work presented in Chapter 7, information from Ottens et al. was used and 
extrapolated to process conditions (Ottens et al., 2004). However, the extrapolation was not 
addressed experimentally. It is possible that nucleation inhibition does not follow a linear 







8.2.3 Classification of seed loads 
In Chapter 7 a reaction crystallization scheme was developed in which seeds were used to 
promote secondary nucleation. However, for simplification purposes, these experiments were 
based on crystal mass.  It is well known that crystal surface can influence the rate of secondary 
nucleation (Doki et al., 2002; Tseng et al., 2014). To quantify the effect of crystal surface area, 
quantification of seeds crystal size distribution is required. This information can be used to 
estimate the total available surface area and relate it to the rate of secondary hydrolysis. An 
alternative to this approach is seed classification. Seeds can be classified into multiple lengths, 
and these classes can be used as seeds in the process. Hence, the effect of increasing or 









A.1 Analytical methods 
A.1.1 HPLC analysis for chiral compounds 
HPLC analyzes were performed to calculate the concentration of species in solution. For 
illustration purposes, calibrations of semi-synthetic 𝛽-lactam substrates and products will be 
shown. Regardless the component of interest, the procedure will be similar. First, a stock 
solution of each component was prepared. Since most of the reactions performed in this thesis 
were at high concentrations, stock solutions were prepared to a concentration close to solubility.  
Stock solutions were used to prepare solutions at lower concentrations by diluting it with the 
desired solvent (water or buffer).  Finally, an aliquot of 50 µL of each solution was diluted into 1 
mL of HPLC buffer. An illustration of a typical chromatogram is shown in Figure A1 while their 
respective calibration curves are shown in Figure A2. 








Figure A.1.2: Calibration curves of (a) 6-APA and D-PGME and (b) ampicillin and D-
phenylglycine at pH of 6.5 and 298K.  
y = 4E-05x + 5.1798
R² = 0.9985




























y = 1E-05x + 0.7787
R² = 0.9956































In order to verify the effect of pH to the calibrations curves, the same procedure was done but the 
pH in solution was raised to 7.0.  As it can be seen in Figure A.3, there is only some deviation in 
peaks retention time. However, data from calibrations performed at a pH of 6.5 and 7.0 were 
combined and shown in Figure A.4. As it can be seen the concentration at both pHs lie on the 
same linear trend. 
 








Figure A.1.4: Calibration curves of (a) 6-APA and D-PGME and (b) ampicillin and D-
phenylglycine at pH of 6.5 and 7.0 and 298K.  
y = 4E-05x + 4.4408
R² = 0.9964



























y = 2E-05x + 0.5218
R² = 0.9889































A.1.2 Utilization of polarimetry and refractometry 
In chapter 3 and 6, polarimetry and refractometry were used as part of an online monitoring 
system that allows real time concentration measurements. As mentioned in these chapters, a 
small portion of crystallizer solution was continuously recirculated through a polarimeter and 
refractometer. In order to estimate concentration from these signals, a calibration curve was 
necessary. Figure A.5 shows an example of ampillin calibration curves using polarimetry and 
refractometry. The calibration curve was prepared by adding a known weight of solute to the 
crystallizer and measuring the respective increment in polarimetric signal and regractive index. 
As it can be seen, both unit give a linear relation between signal and concentration. 
 
 















































































A.2 Supporting Information 
A.2.1 Optimization initial conditions 









60.0 60.0 0.0 0.0 
 
A.2.2 Effect of changing the substrates ratio at different pH values 
In order to verify if the pH value significantly affects the selectivity as a function of substrate 
ratio, the slopes of synthesis vs. hydrolysis ratio as a function of substrate concentration has been 
plotted at different pH values. It can be seen that the slope of this graph is significantly smaller to 
the ones that quantify the effect of substrate concentration. In fact, depending on the specific pH 
value the substrate ratio is in the range of 3.7 to 6.0 more significant than the pH value. 
Table A.2.2: Analysis of substrate ratio and pH value slopes 
 
pH  Slopes of Figure 5.3 Slopes Figure 5.3 
divided by slope of 
Figure 5.4 
6.00 1.49 5.96 
7.00 1.052 4.21 
7.50 1.16 4.64 










A.2.3 Ampicillin crystallization kinetics covariance matrices 
Table A.2.3: Covariance matrix for a single experiment (Run f). 
 kB1 kG g kB2 b s 
kB1 1.06E+21 -35752.7 -3.3E+09 -2.1E+20 -2.8E+09 -5.2E+11 
kG -35752.7 5.28E-12 -1.9E-07 -11389 -5.7E-07 -5.5E-05 
g -3.3E+09 -1.9E-07 0.037376 2.14E+09 0.069852 7.053434 
kB2 -2.1E+20 -11389 2.14E+09 1.31E+20 4.4E+09 4.34E+11 
b -2.8E+09 -5.7E-07 0.069852 4.4E+09 0.399479 11.77837 
s -5.2E+11 -5.5E-05 7.053434 4.34E+11 11.77837 1569.756 
  
Table A.2.4: Covariance matrix for seeded experiments. 
 kB1 kG g kB2 b s 
kB1 1.54E+20 -10764.1 1.31E+08 -1.3E+18 7649648 -1.4E+08 
kG -10764.1 7.93E-13 -5.3E-09 87.76328 -1.6E-09 6.33E-09 
g 1.31E+08 -5.3E-09 0.001519 -463040 -0.00026 -0.00127 
kB2 -1.3E+18 87.76328 -463040 1.14E+16 -426921 60641.8 
b 7649648 -1.6E-09 -0.00026 -426921 0.000267 0.000194 
s -1.4E+08 6.33E-09 -0.00127 60641.8 0.000194 0.002895 
  
Table A.2.5: Covariance matrix for all experiments. 
 kB1 kG g kB2 b s 
kB1 2E+18 -90.3629 -2771924 -1.3E+16 -3154326 -7165773 
kG -90.3629 9.71E-15 5.03E-10 0.24867 1.17E-10 2.3E-10 
g -2771924 5.03E-10 0.000102 61968.39 -1.8E-05 -7.4E-05 
kB2 -1.3E+16 0.24867 61968.39 2.44E+14 -12692.2 -24844.5 
b -3154326 1.17E-10 -1.8E-05 -12692.2 4.31E-05 -2.1E-05 







A.2.4 Effect of cosolute to the solubility of ampicillin at low pH 
In order to understand the effect of cosolutes to the solubility of ampicillin, solutions with 
different cosolute concentrations were prepared and the solubility of ampicillin in theses was 
measured. The fist column of Table A.2.4 shows the concenteration of colute, the second column 
shows the solubility of ampicillin, and the last column shows the ratio of the solubility compared 
with a solution wihout cosolute. In that column we can clearlyu see if the cosolute increases, 
decrease, or does not affect the solubility of ampicillin. All the samples were taken at 25 oC and 
in a pH range of 5-6.5. In that range ampicillin is arounf its isoelectric point and the solubility is 
barely affected by the pH value. 







0.00 44.27 1.00 
3.13 35.34 0.80 
6.26 40.95 0.93 
12.52 38.03 0.86 
25.05 33.28 0.75 







0.00 41.09 1.00 
25.05 51.95 1.26 
50.09 54.18 1.32 
100.18 53.64 1.31 
200.36 59.67 1.45 







0.00 40.76 1.00 
24.34 40.22 0.99 
48.69 37.80 0.93 
97.37 38.70 0.95 
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